Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
07/2012 | Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions July category listing 07/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/26/2012 > 149 patent applications in 127 patent subcategories. category listing

20120190609 - Method for producing a lipid particle, the lipid particle itself and its use: A method for producing a lipid particle comprising the following: i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in ii) and... Agent:

20120190610 - Tetranectin-apolipoprotein a-i, lipid particles containing it and its use: A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one... Agent:

20120190611 - Method for treatment of inflammatory disease and disorder: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.... Agent:

20120190612 - Methods of treatment: The present invention relates to methods for inhibiting proliferation and/or migration of lymphatic endothelial cells and for inhibiting lymphangiogenesis, comprising administering to a subject, or to lymphatic endothelial cells derived therefrom, an effective amount of a collagen type IV-derived NC1 domain polypeptide or a fragment, derivative or variant thereof, a... Agent: Crc For Asthma And Airways Ltd.

20120190613 - Echinocandin derivatives: The invention features echinocandin class compounds that have been modified to (i) have activity against one or more fungal species or genera; (ii) have increased aqueous solubility; (iii) have an increased therapeutic index; (iv) be suitable for topical administration; and/or (v) be suitable for oral administration. The echinocandin class compounds... Agent:

20120190614 - Hcv protease inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20120190615 - Methods and compositions for inducing weight loss: The present invention provides compositions and methods for inducing weight loss, preventing weight gain, and/or treating obesity-related conditions such as diabetes by inducing the production of brown adipose tissue in subjects by administering orexin or biologically active fragments thereof.... Agent: Sanford-burnham Medical Research Institute

20120190616 - Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues... Agent: Ipsen Pharma S.a.s.

20120190617 - Niacin and/or trigonelline as a muscle stimulant: This invention relates to the use of niacin and/or trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity.... Agent:

20120190618 - Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type ii diabetes: The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for... Agent:

20120190619 - Methods of identifying anti-inflammatory compounds: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing WIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune... Agent: The Rockefeller University

20120190620 - Methods to identify targets and molecules regulating purinosomes and their uses: The present invention discloses methods to identify targets, pathways and molecules regulating purinosomes and their uses for treating pathophysiological disorders associated with purinosomes. Disclosed are methods related to both label-free cellular assays and fluorescence imaging to confirm the regulatory roles of various targets and molecules in purinosome dynamics. Disclosed are... Agent:

20120190621 - Corneal endothelial cell proliferation promoter: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on... Agent: Senju Pharmaceutical Co., Ltd.

20120190622 - Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other... Agent: The Regents Of The University Of Michigan

20120190623 - Inactivation resistant factor viii: The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid... Agent: University Of Michigan

20120190624 - Psi-epsilon rack peptide composition and method for protection against tissue damage due to ischemia: A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120190625 - Novel peptide and use thereof: m

20120190626 - Amyloid beta fibrillogenesis-inhibiting peptide: The present invention provides a peptide which functions as a mimic peptide of an amyloid β peptide and is capable of inhibiting the fibrillogenesis of an amyloid β peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following... Agent: Kagoshima University

20120190627 - Cosmetic use of lacritin-type polypeptides: The present invention is directed to the use, in particular cosmetic use, of an effective amount of at least one lacritin-type polypeptide, of an analogue thereof or of a fragment thereof, of at least one nucleic acid sequence encoding this polypeptide, or of at least one agent that modulates the... Agent: L'oreal

20120190628 - Genes and polypeptides relating to human colon cancers: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the... Agent: Oncotherapy Science, Inc.

20120190629 - Light-receiving channel rhodopsin having improved expression efficiency: Disclosed is a Volvox carteri-derived light-receiving channel rhodopsin with an improved expression efficiency on a cell membrane. Specifically disclosed is a modified Volvox carteri-derived light-receiving channel rhodopsin protein. The protein is modified to contain an N-terminal region of Chlamydomonas reinhardtii-derived channel rhodopsin-1 at the N-terminal of the Volvox carteri-derived light-receiving... Agent: Tohoku University

20120190630 - Amino acid-based compounds, their methods of use, and methods of screening: Described herein are compounds that comprise amino acids and their pharmaceutical compositions. Methods used to administer the compounds are described. Screening methods including those for determining... Agent: The Administrators Of The Tulane Educational Fund

20120190631 - Materials and methods relating to glycosylation: Techniques to glycosylation are described, and more particularly to the production of glycosylation structures that are resistant to enzymatic degradation, thereby modulating one or more of their biological properties or those of therapeutic moieties incorporating them, and in particular to reacting activated carbohydrate substrates containing fluorine, such as 3-fluoro sialic... Agent:

20120190632 - Anti-bacterial infection, inflammation, and leukemia composition and use thereof: A method of inhibiting the growth of Gram-positive bacteria comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is provided. The Gram-positive bacteria comprise methicillin-resistant Staphylococcus aureus. A method of treating sepsis comprising administering an effective amount of Tellimagrandin II,... Agent: Kaohsiung Medical University

20120190634 - Lipoteichoic acid-derived glycolipids, and compositions comprising same: A lipoteichoic acid (LTA)-derived glycolipid, and a pharmaceutical, food or cosmetic composition and a vaccine adjuvant including the same are provided. The LTA-derived glycolipid can inhibit the production of inflammatory cytokines and thus have anti-inflammatory effects. Therefore, the pharmaceutical, food or cosmetic compositions including the LTA-derived glycolipid can be used... Agent: Rna Inc.

20120190633 - Monophosphorylated lipid a derivatives: The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided.... Agent:

20120190635 - Selective oxidation of c-h bonds of modified substrates by p450 monooxygenase: The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate.... Agent: The Regents Of The University Of Michigan

20120190636 - Composition for prophylaxis or treatment of urinary system infection and method thereof: The present invention relates to a method of reducing risk of recurrent urethritis or recurrent cystitis comprises administering to a patient with risk of recurrent urethritis or recurrent cystitis an effective amount of a composition consisting essentially of astilbin and chlorogenic acid.... Agent:

20120190637 - Combination therapy treatment for viral infections: Therapeutics which employ a combination of an antiviral agent and an EP4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza A virus, for example H1N1, H3N2 and H5N1, and mutations thereof, and/or a coronavirus, for example a... Agent: Gemmus Pharma, Inc.

20120190728 - Compositions and methods for modulation of smn2 splicing in a subject: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.... Agent:

20120190726 - Functionalized polysaccharides for active agent delivery: Embodiments of the invention include functionalized polysaccharides and compositions and structures including the same. In an embodiment, the invention includes an active agent delivery composition including a polysaccharide functionalized with a coupling group, wherein the polysaccharide lacks charged groups at a pH of between 6 and 8; and a complex... Agent:

20120190727 - Method and means for treatment of osteoarthritis: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a... Agent: Galapagos Nv

20120190729 - Mirna inhibition of six1 expression: The invention provides a method of treating cancer in a subject comprising administering to said subject an miRNA that inhibits Six1. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject.... Agent: The Regents Of The University Of Colorado A Body Corporate

20120190731 - Methods and compositions to reduce oxidative stress: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells... Agent: University Of Massachusetts

20120190732 - Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing: The present invention provides compositions comprising a ligand-nucleic acid nanostructure that promote tumor cell-specific killing and methods of using the compositions. Specially, the invention provides aptamer-nucleic acid nanostructures for treating tumors in a mammal. The methods of making the compositions are also provided.... Agent: Arizona Board Of Regents

20120190730 - Targeting cells with altered microrna expression: The present invention relates to a method of modulating development of a cell. The method includes the step of introducing into the cell a nucleic acid with the capacity to modulate development of the cell, the nucleic acid including a target site for binding of a microRNA, wherein the activity... Agent: Vimar S.p.a.

20120190638 - Methods of treating hematologic cancers: This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are... Agent: Mayo Foundation For Medical Education And Research

20120190639 - Treatment or prophylaxis of proliferative conditions: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use... Agent: University Court Of The University Of Dundee

20120190640 - Cyanocobalamin low viscosity aqueous formulations for intranasal delivery: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7%... Agent: Par Pharmaceuticals Inc.

20120190643 - Carbohydrate composition for flat glucose response: s

20120190642 - Isoflavones for treating mucopolysaccharidoses: A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone... Agent: Instytut Farmaceutyczny

20120190641 - Use of non-digestible oligosaccharides: Use of a non-digestible oligosaccharide or salt thereof for producing an anti proliferative effect in a subject wherein the non-digestible oligosaccharide is of formulae (i) [A]-[B]n Formula 1 wherein A and B are each independently a five or six membered saccharide unit and n is 2 to 10.... Agent: The University Of Manchester

20120190644 - Viscoelastic gels as novel fillers: e

20120190645 - Organic compounds: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment... Agent:

20120190646 - Compositions comprising thalidomide and artemisinin for the treatment of cancer: The present invention relates to pharmaceutical compositions for the treatment of cancer and especially for the treatment of hematological malignancies such as multiple myeloma. Specifically, the present invention relates to pharmaceutical composition for the treatment of cancer comprising: thalidomide, or a derivative thereof, or salts or solvates thereof; one or... Agent:

20120190647 - Novel oral forms of a phosphonic acid derivative: Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using... Agent:

20120190649 - Bicyclic aryl sphingosine 1-phosphate analogs: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Biogen Idec Ma Inc.

20120190648 - Fluorinated cyclopropane analogs of glutamic acid: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C1-C6)alkyl or (C1-C6)alkenyl group, optionally substituted by one or... Agent:

20120190650 - Inhibitors of autotaxin: Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.... Agent: University Of Tennessee Research Foundation

20120190651 - Anti-inflammatory compounds: This invention relates to novel compounds obtained by fermentation of Myxobacteria strain (PM0670013/MTCC 5570). The present invention further relates to the processes for the production of the novel anti-inflammatory compounds, to the culture no. PM0670013 (MTCC 5570), and to pharmaceutical compositions containing compounds of the present invention as an active... Agent: Piramal Life Sciences Limited

20120190652 - Diagnostic agent for parkinson's disease: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD in the pre-symptomatic phase of the disease or to distinguishing PD from another neurological disorder. The... Agent: United Arab Emirates University

20120190653 - Therapeutic eye drop comprising doxycycline and a stabilizer: The present invention provides stable aqueous doxycycline aqueous solutions suitable for pharmaceutical, especially ophthalmic, use. The doxycycline aqueous solutions have a pH ranging from 4.5-8, and contain an antioxidant and a stabilizer such as caffeine, creatine or mixtures thereof. The solutions have improved lifetimes and can be used topically.... Agent: Advanced Vision Research, Inc.

20120190654 - Novel bicyclic urea compounds: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.... Agent: Merck Patent Gmbh

20120190655 - Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine: An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture. The theanine enantiomer may be L-theanine, D-theanine, or DL-theanine... Agent: Theraprin Pharmaceuticals, Inc.

20120190656 - Methods for selecting therapies to improve hdl cholesterol and triglyceride levels: Disclosed herein are diagnostic methods for determining whether subjects will be responsive to vitamin D therapy. The methods involve the detection of one or more single nucleotide polymorphisms in a test sample, in combination with other clinical factors. The tests are suitable for diagnosing and determining a treatment regime for... Agent:

20120190657 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20120190658 - Method and composition for the treatment of adverse skin conditions: A multi-component medicament composition for the treatment of adverse skin conditions such as eczema or psoriasis comprises a combination of a steroid and silicone.... Agent:

20120190660 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-ethynylphenyl derivatives, methods for the production thereof and use thereof for treating diseases: m

20120190659 - Angiogenesis inhibitors: Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:... Agent: President And Fellows Of Harvard College

20120190661 - Androgen composition for treating an opthalmic condition: The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.... Agent:

20120190662 - Pharmaceutical propylene glycol solvate compositions: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.... Agent:

20120190663 - Use of free dna as an early predictor of severity in acute pancreatitis: This invention provides methods of determining the risk of AP development in an individual, as well as the diagnosis, prognosis, and treatment of acute pancreatitis (AP) in an individual, by determining the presence or absence of significantly high levels of free serum DNA in the subject relative to levels in... Agent: Cedars-sinai Medical Center

20120190664 - Process for the preparation of antibiotic compounds: The present invention relates to a process for the preparation of carbapenem antibiotic compounds, which are useful for intravenous and intramuscular administration.... Agent: Savior Lifetec Corporation

20120190665 - Pyrazolopyrimidine jak inhibitor compounds and methods: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and... Agent: Genentech, Inc.

20120190666 - Heteroaryl compounds as pikk inhibitors: The present invention provides compounds that are PIKK inhibitors, more specifically, mTOR and/or PI3Kα kinase inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PI3 kinases, more specifically, mTOR and/or PI3Kα, such as cancer. Also provided are pharmaceutical compositions containing such compounds and... Agent: Amgen Inc.

20120190667 - Method of making solid dispersions of highly crystalline therapeutic compounds: A process for preparing solid dispersions of highly crystalline compounds. The highly crystalline or thermally labile therapeutic compounds are processed in an extruder in combination with a solubilizing agent and optionally a plasticizer. The resulting extrudate features the therapeutic compound in an amorphous state. Particularly useful as the solubilizing agents... Agent:

20120190668 - Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity: The present invention provides methods for enhancing cellular transplantation by exposing cells in vitro or ex vivo, or a recipient of cells, to a small molecule hepatocyte growth factor/scatter factor mimetic. Exemplary compounds are described.... Agent:

20120190669 - Oxindole compounds: The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation.... Agent: Cylene Pharmaceuticals, Inc.

20120190671 - Controlled-release cns modulating compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).... Agent: Otonomy, Inc.

20120190670 - Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anti-convulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting... Agent:

20120190672 - Fused aminodihydrothiazine derivatives: e

20120190673 - Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases: The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes... Agent: Astex Therapeutics Limited

20120190674 - Sulfonamides as trpm8 modulators: e

20120190675 - Azaspirohexanones: wherein the variables R1, R2, R3, R4, R7, A, Z and m are as defined herein. The compounds of formula (I) are inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic... Agent: Boehringer Ingelheim International Gmbh

20120190676 - Inhibitors of mtor kinase as anti-viral agents: The present invention provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein... Agent:

20120190677 - Novel tetrahydroquinoline derivatives: e

20120190678 - Substituted pyrazolo-quinazoline derivatives as kinase inhibitors: The present invention relates to substituted pyrazolo[4,3-h]quinazoline compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular PIM kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of... Agent:

20120190679 - Novel protein kinase b inhibitors - 060: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods... Agent: Astrazeneca Ab

20120190680 - Heteroaryl amide analogues: In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2X7 receptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system... Agent: H. Lundbeck A/s

20120190681 - Picolinamide inhibitors of kinases:

20120190682 - Modulators for amyloid beta: wherein R1, R2, R3, R4, and Ar are as defined in the specification and claims, or to pharmaceutically active acid addition salts of such compounds. Compounds of formula I are modulators for amyloid beta and may be useful for the treatment or prevention of a disease associated with the deposition... Agent:

20120190683 - Insecticidal substituted azinyl derivatives: N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects.... Agent: Dow Agrosciences LLC

20120190684 - Insecticidal substituted azinyl derivatives: N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects.... Agent: Dow Agrosciences LLC

20120190685 - Novel phenylimidazole derivative as pde10a enzyme inhibitor: This invention provides the compound 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]thazolo[1,5-a]pyrazine and pharmaceutically acceptable acid addition salts thereof.... Agent: H. Lundbeck A/s

20120190686 - Bicyclo[3.2.1]octyl amide derivatives and uses of same: i

20120190687 - Pyrazinylpyrazoles:

20120190688 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent:

20120190689 - Piperazinyl 3-aminopyrrolidine derivatives as a ccr2 antagonist: s

20120190690 - Eltoprazine for the treatment of weight disorders: The present invention relates to the treatment of an individual afflicted with a weight disorder, particularly obesity, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof.... Agent: Merz Pharma Gmbh & Co. Kgaa

20120190691 - Pharmaceutical compositions for treatment of respiratory and inflammatory diseases: The present invention relates to pharmaceutical composition comprising a CRTH2 antagonist and at least one histamine receptor antagonist, medicaments containing said pharmaceutical compositions, and the use of said pharmaceutical compositions for treating respiratory and inflammatory diseases and conditions.... Agent: Boehringer Ingelheim International Gmbh

20120190692 - Selective substituted pyridine ligands for neuronal nicotinic receptors: e

20120190693 - Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.... Agent:

20120190695 - Phenyloxadiazole derivatives as pgds inhibitors: wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration... Agent: Sanofi

20120190694 - Selective sphingosine-1-phosphate receptor antagonists: Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) receptor modulation.... Agent: Allergan, Inc.

20120190696 - Inhibitors of fatty acid binding protein (fabp): The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (FABP) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance... Agent: Schering Corporation

20120190697 - Hiv inhibiting bicyclic pyrimidine derivatives: e

20120190698 - Methods of predicting thiopurine response: The present invention relates to methods of predicting therapeutic efficacy of thiopurines in an individual by determining the presence of one or more risk variants. In one embodiment, the effective therapeutic efficacy of thiopurines is determined by the presence of risk variants at the genetic loci of HLA-DRB1, CREM, TAGAP,... Agent: Cedars-sinai Medical Center

20120190699 - Pyridones useful as inhibitors of kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing the compounds of the invention and... Agent: Vertex Pharmaceuticals Incorporated

20120190700 - Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer: e

20120190701 - Renin inhibitors: Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6-alkyl or C3-6-cycloalkyl, wherein said C1-6-alkyl or... Agent: Merck Sharp & Dohme Corp.

20120190702 - Use of methylnaltrexone and related compounds to treat constipation in chronic opioid users: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with... Agent: The University Of Chicago

20120190703 - Salts of 13a-(s)desoxytylophorinine, preparation methods and pharmaceutical compositions and uses thereof: The present invention relates to the salts of (+)-13a-(S)-deoxytylophorinine represented by the general formula (I), the preparation method thereof, the pharmaceutical compositions containing them, and their use as medicaments for prevention and/or treatment of cancer and/or inflammation disease.... Agent: Institute Of Mataria Medica, Chinese Academy Of Medical Sciences

20120190704 - Azaadamantane ester and carbamate derivatives and methods of use thereof: The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent:

20120190705 - Methods of inhibiting choroidal neovascularization: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.... Agent:

20120190706 - Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof: The invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent:

20120190707 - Selective inhibitors of akt and methods of using same: The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase. In general, the method comprises: (1) providing a plurality of compounds suspected of having Akt1 kinase inhibitory activity; (2) modeling the docking of each of the plurality of the... Agent:

20120190708 - Targeting nad biosynthesis in bacterial pathogens: The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule... Agent: Sanford-burnham Medical Research Institute

20120190709 - Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof: This invention relates to novel 4-(indazol-5-yl)-4,7-dihydroisoxazolo[5,4-b]pyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120190710 - Bicyclo-heptan-2-amines: The present invention provides bicyclo-heptan-2-amines that selectively bind to the sigma-2 receptor and are useful in the treatment of diseases related to the sigma-2 receptor, for example, cancer and neurological disorders.... Agent: Adeboye Adejare

20120190711 - Lenalidomide salts: The present invention relates to acid addition salts of lenalidomide, wherein said acid has a pKa lower than 1, preferably selected from hydrochloric acid, hydrobromic acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid and p-toluenesulfonic acid, to processes for their making, and use in medicine, and to purification... Agent:

20120190712 - Methods for treating cognitive disorders: Disclosed herein are methods of treating a patient suffering a cognitive disorder.... Agent:

20120190713 - Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections: s

20120190714 - Alpha ketoamide compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Virobay, Inc.

20120190715 - Highly penetrating compositions and methods for treating pathogen-induced disordered tissues: Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence... Agent:

20120190716 - Methods and uses of cytochrome p450 inhibitors: Methods are provided for treating or preventing chronic obstructive pulmonary diseases such as emphysema, and fibrotic diseases including heart, liver, kidney and vascular diseases, by administering to a subject a pharmaceutical composition comprising a compound that inhibits cytochrome P450RA or CYP26.... Agent:

20120190717 - Methods and compositions for increasing the anaerobic working capacity in tissues: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.... Agent: Natural Alternatives Internatioal, Inc.

20120190718 - Diarylthiohydantoin compounds: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.... Agent: The Regents Of The University Of California

20120190719 - Methods of treating motor disorders with alpha-2b andrenergic receptor agonists: Disclosed herein is a method of treating compulsive disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist.... Agent: Allergan, Inc.

20120190720 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.... Agent: Abbott Laboratories

20120190721 - Method for treating nervous system disorders and conditions: The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain.... Agent: Wyeth LLC

20120190722 - Ketorolac tromethamine compositions for treating or preventing ocular pain: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.... Agent: Allergan, Inc.

20120190723 - Viral modulators and processes thereof: A viral modulator and process thereof. A method may include contacting one or more viral modulators to one or more biological systems. A biological system may be configured to be infected by one or more virus. A virus may include an HIV virus, a VEEV virus and/or the like. A... Agent:

20120190724 - Novel anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same: The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.... Agent: Ewha University Industry Collaboration Foundation

20120190725 - Inhibitor(s) of transporters or uptake of monoaminergic neurotransmitters: where at least one of R1-R4 is a heterocycle, at least one of R1-R4 is an aryl group coupled to the ring by a linker atom, functional group, or other moiety, or where none of R1-R4 is an amide, and any and all combinations thereof. Remaining R1-R4 substituents independently are... Agent: State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon

20120190733 - Compounds and methods for enhancing hair growth: The present invention provides a method for stimulating hair growth in a mammalian species or converting vellus hair or intermediate hair to terminal hair or stimulating hair follicles to increase hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or... Agent:

20120190734 - Compounds and compositions for treating infection: Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.... Agent:

20120190735 - Cancer cell apoptosis: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol,... Agent: E-therapeutics PLC

20120190736 - Method of managing broncho-constrictive condition: The present disclosure is in relation to the use of a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutical excipient(s), in management of broncho-constrictive conditions such as Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).... Agent:

20120190737 - Fatty acid formulations and methods of use thereof: The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.... Agent:

20120190738 - Inhibitors of phosphatidylinositol-3-kinase (pi3) and inducers of nitric oxide (no): The present invention relates to compounds of general formula I for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula I for the treatment of malignancy by inhibition of PI3-Akt pathway and... Agent:

20120190739 - Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.... Agent: Gemmus Pharma Inc.

20120190740 - Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury: The present disclosure concerns methods of managing the risk of liver injury in patients receiving treatment with dronedarone or pharmaceutically acceptable salts thereof.... Agent: Sanofi

20120190741 - Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof: The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are... Agent: Shandong Luye Pharmaceutical Co. Ltd.

20120190742 - Method for treating eczema: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.... Agent:

20120190743 - Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity: Compounds, pharmaceutical compositions and methods of treating a disorder or disease associated with neurokinin 2 (NK2) receptor activity.... Agent: United Paragon Associates Inc.

20120190744 - Preservative system for cosmetic formulations- compositions and methods thereof: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.... Agent:

20120190745 - Oral composition for reducing wrinkle formation: Provided is a novel composition that acts to inhibit and/or ameliorate wrinkle formation, does not have adverse effects like those of retinoids, and is highly photostable. An oral composition for reducing wrinkle formation and an oral composition for preventing wrinkle formation are provided, the compositions containing at least one compound... Agent: Shiseido Company. Ltd.

20120190746 - Aflatoxin production inhibitor and method for controlling aflatoxin contamination using the same: o

20120190747 - Method of treatment using fatty acid synthesis inhibitors: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.... Agent:

20120190748 - Greater utility with thyroid hormone: Formulations and delivery systems that include a thyroid hormone active agent consisting essentially of T4 should reduce fluctuations in delivery of thyroid hormone.... Agent:

20120190749 - Sterilization method: It is an object of the present invention to provide a novel sterilization method capable of killing not only microorganisms in water, but also microorganisms in a gas. Specifically, the present invention provide a method for sterilizing a gas or liquid, comprising contacting a microorganism in a gas or liquid... Agent: Tokyo Institute Of Technology

20120190750 - Stable ready to use injectable paracetamol formulation: The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of hydroxyalkyl-cyclodextrins and at least one stabilizing compound, being EDTA or monothioglycerol, alone or in combination, in a concentration between 0.001% and... Agent: Uni-pharma Kleon Tsetis Pharmaceutical Laboratories S.a.

20120190751 - Compounds for treatments of inflammation: The present invention relates to the use of benzylideneaminoguanidines for the treatment of inflammation and pain. In one preferred embodiment, the invention relates to the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine for the treatment of rheumatoid arthritis.... Agent: Ana-mar Ab

20120190752 - Exo-s-mecamylamine method, use, and compound for treatment: The present invention relates to exo-S-mecamylamine and the use of exo-S-mecamylamine in medical treatments.... Agent: Targacept Inc.

20120190753 - Compositions containing aromatic aldehydes and their use in treatments: Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.... Agent: Merz Aesthetics, Inc.

20120190754 - Antimicrobial composition containing parachlormetaxylenol: A biocidal composition is provided comprising a complex of parachlorometaxylenol and a polycarbocylic acid or a salt thereof. A surfactant can be added to the composition to form a biocidal cleaning composition. The composition can be added to a latex or hot melt polymeric composition to form a biocidal polymeric... Agent: Sentinel Products Corp.

20120190755 - Reactive 1-component roadway marking: The invention relates to a one-component, storage-stable formulation for marking road surfaces. The invention in particular relates to a formulation for roadway marking comprising encapsulated radical initiators which do not influence the storage stability of the roadway marking and are simple to break open upon application in order to release... Agent: Evonik Roehm Gmbh

20120190756 - Dendritic polyether-polyurethane thickeners: Described are associative polyether-polyurethane thickeners into which dendritic polyetherpolyols have been polymerized-in. Also described is the preparation of these thickeners, and the use thereof, in particular, in cosmetic preparations.... Agent: Basf Se

20120190757 - Formulations and methods for solid chitosan-containing blends: Chitosan-containing blends and methods of dissolving and using chitosan are disclosed. A blend includes a solid acid or a solid agent that generates a proton in situ in the presence of water mixed together with a dry solid chitosan, and may optionally contain other components. The blends are in a... Agent: Halosource, Inc.

  
07/19/2012 > 151 patent applications in 117 patent subcategories. category listing

20120184480 - Use of constrained dipeptide and tripeptide mimic oligomers as vectorization agents: The invention relates to the use of oligomers having constrained dipeptide or tripeptide motifs as agents for the vectorization of active ingredients.... Agent: Centre National De La Recherche Scientifique (cnrs)

20120184481 - Variants of pigment epithelium derived factor and uses thereof: The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF... Agent: Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science

20120184482 - Novel ubiquitin-isopeptide probes: The invention relates to a ubiquitin-isopeptide probe (hereinafter also referred to as UIPP), a method for its preparation, and its use. The invention also provides a method for isolating a deubiquitinating enzyme and a method for activity-based protein profiling (ABPP).... Agent: Helmholtz-zentrum Fuer Infektionsforschung Gmbh

20120184484 - Lactoferrin and brain health and development in infants: The present invention relates generally to the field of brain development and brain health. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed brain development and/or a delayed development of the nervous system. Also cognitive performance can... Agent: Nestec S.a.

20120184483 - Lactoferrin and neuronal health and development in the infant gut: The present invention relates generally to the field of neuronal health, neuronal protection and neuronal development. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed development of the enteric nervous system. Neuronal cells in the gut can... Agent: Nestec S.a.

20120184485 - Uses of cystatin: The present invention relates to uses of cystatins derived from nematodes and to a method of screening using such cystatin. The present invention also relates to methods of treatment and/or prevention of an allergic and/or autoimmune disease in a patient, using a cystatin derived from a nematode.... Agent:

20120184486 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).... Agent: Pfizer Inc.

20120184488 - Insulin analogues of enhanced receptor-binding specificity: A method of treating a patient includes administering a physiologically effective amount of an insulin analogue or a physiologically acceptable salt thereof to the patient. The insulin analogue or physiologically acceptable salt thereof contains an insulin A-chain sequence modified at positions selected from the group consisting of A0, A1, A4,... Agent: Case Western Reserve University

20120184487 - Insulin derivatives: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.... Agent: Novo Nordisk A/s

20120184489 - Prodrugs comprising an insulin linker conjugate: wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated... Agent: Sanofi-aventis Deutschland Gmbh

20120184490 - Enhancement of bmp retention: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of... Agent: The Regents Of The University Of California

20120184491 - Methods and compound to inhibit ca2+ permeable cation conductance: The present invention provides methods and compositions for inhibiting calcium permeable cation conductance of red blood cells from individuals afflicted with sickle cell anemia. The method comprises exposing the cells to the peptide GsMTx4 and/or variants thereof.... Agent:

20120184492 - Therapeutic use of a growth factor, nsg33: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and... Agent: Nsgene A/s

20120184493 - Dermal formulations of dp2 receptor antagonists: Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal. Topical formulations disclosed herein include a DP2 receptor antagonist compound formulated for dermal administration... Agent: Panmira Pharmaceeuticals, LLC

20120184494 - Multiple myeloma prognosis and treatment: Disclosed herein are diagnostic and prognostic methods for determining the overall survival, and therapeutic regimes, for multiple myeloma patients. The methods involve the detection of PTHR1 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring treatment of patients having or suspected... Agent:

20120184495 - Targeted nano-photomedicines for photodynamic therapy of cancer: The present invention relates to a photosensitizer-containing nanoparticle, comprising a photosensitizer covalently bonded throughout at least a part of said nanoparticle to the nanoparticle matrix material and incorporated therein in a quasi-aggregated state. The present invention further relates to methods for producing the invention nanoparticles, and to methods of killing... Agent: Erasmus University Medical Center Rotterdam

20120184496 - Ophthalmic pharmaceutical compositions of dp2 receptor antagonists: Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP2 receptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.... Agent: Panmira Pharmaceuticals, LLC

20120184497 - Dalbavancin compositions for treatment of bacterial infections: The invention provides dosage forms and compositions for treatment of bacterial infections. The dosage form may include a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle. The dosage form may include a dalbavancin factor B0 and at least one additional dalbavancin factor among A0, A1,... Agent:

20120184498 - Dermaseptin b2 used as an inhibitor of the growth of a tumor: The invention relates to the use of peptides corresponding to dermaseptin B2 or fragments thereof for treating proliferative diseases such as cancer or ocular lesions, and to pharmaceutical compositions containing such peptides.... Agent: Universit&#xc9 Pierre Et Marie Curie (paris 6)

20120184499 - Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity: The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Pseudolysimachion genus plant and the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL-13 levels and... Agent: Korea Research Institute Of Bioscience And Biotechnology

20120184500 - Stevia extract or steviol for hair care: This invention relates to the use of an oral composition comprising Stevia extract, steviol precursors, or steviol which enhances the appearance of hair. It further relates methods of improving the appearance of hair by oral administration of an effective amount of Stevia extract, steviol precursors or steviol.... Agent:

20120184501 - Antibacterial aminoglycoside analogs: i

20120184502 - Optimised formulation of tobramycin for aerosolization: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused... Agent: Chiesi Farmaceutici S.p.a.

20120184595 - Compositions and methods for silencing apolipoprotein c-iii expression: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g.,... Agent: Protive Biotherapeutics, Inc.

20120184600 - Inhibition of glycerol-3-phosphate acyltransferase (gpat) and associated enzymes for treatment of viral infections: A method of treating or preventing a viral infection in a mammal by administering a compound or pharmaceutically acceptable derivative thereof that inhibits a phosphatidic acid synthesis enzyme... Agent:

20120184596 - Microrna inhibitors comprising locked nucleotides: The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-208 family miRNAs, including miR-208a, miR-208b, and/or miR-499. The invention provides in some embodiments, oligonucleotides capable of inhibiting, in a specific fashion, the expression or abundance of each of miR-208a, miR-208b, and miR-499. The invention further... Agent: Miragen Therapeutics

20120184597 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a... Agent: Quark Pharmaceuticals Inc.

20120184598 - Polynucleotides for multivalent rna interference, compositions and methods of use thereof: The present invention includes bivalent or multivalent nucleic acid molecules or complexes of nucleic acid molecules having two or more target-specific regions, in which the target-specific regions are complementary to a single target gene at more than one distinct nucleotide site, and/or in which the target regions are complementary to... Agent: Halo Bio Rnai Therapeutics, Inc.

20120184599 - Use of microrna for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells: The present invention relates to a method for evaluating the regenerative and/or differentiation capacity of ciliated epithelial tissue in a vertebrate subject, in particular a mammal, preferably a human, and to the use of microRNA in treating illnesses associated with a dysfunction of multiciliated epithelial cells.... Agent: Centre National De La Recherche Scientifique

20120184601 - Antiviral oligonucleotides: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for... Agent:

20120184602 - Metabolically activated recombinant viral vectors and methods for their preparation and use: Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one... Agent: Genzyme Corporation

20120184603 - Novel human micrornas associated with cancer: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.... Agent: Exiqon A/s

20120184504 - \"the use of a par-1 antagonist in combination with a p2y12 adp receptor antagonist for inhibition of thrombosis\": The treatment and prevention of thrombotic events are provided through co-administration of PAR-1 and the P2Y12 ADP receptor antagonists. Combined inhibition of the PAR-1 and the P2Y12 ADP platelet activation pathways had synergistic antithrombotic and antiplatelet effects, as demonstrated in co-administration of SCH 602539 and cangrelor.... Agent:

20120184503 - Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection: Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.... Agent: Abbott Laboratories

20120184505 - Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrimidine analogs as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator... Agent:

20120184507 - Leaven-based mixture: A mixture obtainable by a process comprising the following steps: a) adding a culture comprising sprouted rye grains and water to a rye fine or coarse meal and subjecting the mixture to a process of heating to 30-34° C. within 3 to 5 hours, a strong maltose formation being initiated... Agent: Woresan Gmbh

20120184506 - Use of sulfated oligosaccharides as slimming cosmetic ingredients: This invention relates to the use of a preparation comprising sulfated oligosaccharides which trap spermine or spermidine or both, as an active slimming ingredient in a cosmetic, pharmaceutical and/or nutraceutical composition. One of the objectives of the invention is to supply a cosmetic, pharmaceutical or nutraceutical composition with a slimming... Agent: Basf Beauty Care Solutions France S.a.s.

20120184509 - Compounds as trvp1 blockers, pharmaceutical compositions and medical uses thereof: A kind of new compounds, and their pharmaceutically acceptable salts, and hydrates are disclosed. The pharmaceutical composition thereof is also provided. And also are the medical uses of the compounds, pharmaceutically acceptable salts, hydrates and the pharmaceutical composition for treating the TRPV1-mediate diseases.... Agent:

20120184508 - Pyrazolo pyrimidines: and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.... Agent:

20120184510 - Cold menthol receptor-1 antagonists: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or... Agent:

20120184511 - Novel pharmaceutical composition comprising a macrolide immunosuppressant drug: The invention provides novel pharmaceutical compositions of macrolide immunosuppressants. The compositions comprise a hydrophilic component, a lipophilic component, and an amphiphilic component. Preferably, the compositions are formulated as liquid microemulsion. Furthermore, the invention provides uses of such compositions, such as for the topical treatment of inflammatory and autoimmune diseases. Methods... Agent: Novaliq Gmbh

20120184512 - Gyrase and topoisomerase iv inhibitors: or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are... Agent: Vertex Pharmaceuticals Incorporated

20120184513 - Organic compounds:

20120184514 - Vitamin d compounds and methods for preparing same: An air-stable, high-melt 1a-hydroxy-vitamin D3 compound, methods for preparing an animal feed composition, methods of preparing 1α-hydroxy-vitamin D3, methods of enhancing phytate phosphorus and calcium utilization, and an animal feed regime are provided.... Agent: Vitamin Derivatives Inc.

20120184515 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases: The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene-11-methyleneoxyalkylenearyl derivative of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas,... Agent: Bayer Pharma Aktiengesellschaft

20120184519 - Compositions and methods for preventing or treating influenza virus infection: The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The... Agent: Philadelphia Health And Education Corporation D/b/a Drexel University College Of Medicine

20120184518 - Methods of treating or preventing an inflammatory disease or condition using glutaminyl cyclase inhibitors: Methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, sepsis and peritonitus. Further provided are respective... Agent: Probiodrug Ag

20120184516 - Sgc stimulators: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.... Agent:

20120184517 - Treatment of diseases with altered smooth muscle contractility: The present invention provides, inter alia, methods and compositions for treating or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma.... Agent:

20120184523 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Exelixis, Inc.

20120184522 - Therapeutic applications in the cardiovascular field of quinazolinedione derivatives: e

20120184520 - Glycine compound: The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular,... Agent: Astellas Pharma Inc.

20120184521 - Substituted amide compound: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or —(CRX1RX2)n—; n is 1, 2, 3, or 4; RX1 and RX2 are hydrogen, etc.; Y1 to Y5 are each CRY or N; each RY... Agent: Astellas Pharma Inc.

20120184525 - 1,2,3-triazolo [4,3-a] pyridine derivatives and thier use for the treatment of prevention of neurological and psychiatric disorders: The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric... Agent: Janssen Pharmaceuticals, Inc

20120184526 - Compounds and compositions as syk kinase inhibitors: Provided herein are a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.... Agent:

20120184524 - Pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20120184527 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors: The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric... Agent: Janssen Pharmaceuticals, Inc

20120184528 - 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors: The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric... Agent: Janssen Pharmaceuticals, Inc

20120184529 - Combination therapy: The present invention relates to a combination therapy of 2-Chloro-N-(4-chloro-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide and 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide for treating a patient suffering from a proliferative disorder.... Agent:

20120184530 - Dimeric iap inhibitors: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.... Agent: Tetralogic Pharmaceuticals Corporation

20120184531 - Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia: m

20120184532 - Galantamine amino acid and peptide prodrugs and uses thereof: Prodrugs of galantamine or its 3-hydroxy metabolite with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and methods for treating a memory or cognition disorder with the galantamine prodrugs are provided herein. Prodrugs having side chains of valine, phenylalanine, tyrosine or para amino benzoic acid and mono-, di-... Agent: Shire LLC

20120184533 - Small molecule inhibitors of parp activity: Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.... Agent: Angion Biomedica Corp.

20120184535 - Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent: A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine and tyrosine kinases and a serine/threonine and tyrosine kinases modulating agent. Novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses... Agent: Selvita S.a.

20120184534 - Tri-cyclic pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20120184536 - Compositions comprising specific ugt inhibitors and methods of use thereof: The present invention encompasses compositions comprising UGT inhibitors. Additionally, the invention encompasses methods of reducing the glucuronidation of a compound using a UGT inhibitor.... Agent: The Board Of Trustees Of The University Of Arkansas

20120184537 - [1,4]-benzodiazepines as vasopressin v2 receptor antagonists: The invention relates to a novel class of [1,4]-benzodiazepine derivatives, processes for their preparation, intermediates usable in these processes, and pharmaceutical compositions containing the compounds. Other aspects of the invention are directed to the use of said [1,4]-benzodiazepine derivatives in therapy based on the capability of said compounds to interfere... Agent: Shire-movetis N.v.

20120184538 - Isoxazolo-pyridine derivatives: e

20120184540 - 1,4 oxazines as bace1 and/or bace2 inhibitors:

20120184539 - Novel heterocyclic derivatives and their use in the treatment of neurological disorders:

20120184541 - Compounds and methods of use: in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for... Agent:

20120184543 - Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof: Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20120184542 - Pyrido pyrimidines: h

20120184544 - Substituted benzamide derivatives as glucokinase (gk) activators: The present invention relates to substituted benzamide derivatives of the general Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites, and polymorphs and can be useful for treating disease states mediated by glucokinase. Compounds disclosed herein can be used for reducing blood glucose levels and... Agent: Cadila Healthcare Limited

20120184545 - Heart-slowing drug containing short-acting beta-blocker as teh active ingredient: The present invention relates to an agent which slows down the heart rate which has an excellent controlling ability in diagnostic imaging comprising a short-acting β-blocker (e.g. landiolol hydrochloride or esmolol hydrochloride). The short-acting β-blocker has a property of slowing down the heart rate and it can temporarily suppress the... Agent: Ono Pharmaceutical Co., Ltd.

20120184546 - [1,2,4]triazolo [1,5-c]pyrimidine derivatives as hsp90 modulators: The present invention relates to [1,2,4]triazolo[1,5-c]pyrimidine derivatives of formula (I) which inhibit the activity of Heat Shock Protein Hsp90. The compounds of the invention are therefore useful in treating proliferative diseases such as cancer and neurodegenerative diseases. The present invention also provides processes for preparing these compounds, methods of treating... Agent: Nerviano Medical Sciences S.r.l

20120184547 - Methods for treating schizophrenia: Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from schizophrenia.... Agent: Afraxis, Inc.

20120184548 - Carboxylic acid aryl amides: o

20120184549 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention... Agent: Boehringer Ingelheim International Gmbh

20120184550 - Substituted nicotinamides as kcnq2/3 modulators: Substituted nicotinamides, processes for their preparation, medicaments comprising these compounds and methods of using these compounds to treat pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, and/or dystonia-associated dyskinesias.... Agent: Grunenthal Gmbh

20120184551 - Combination of brimonidine and timolol for topical ophthalmic use: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.... Agent:

20120184552 - Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin: The invention provides an aqueous eye drop containing latanoprost, a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof. In addition, the invention provides a method of suppressing adsorption of latanoprost to a resin in an aqueous solution, by adding a... Agent: Senju Pharmaceutical Co., Ltd.

20120184553 - Novel compounds: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.... Agent:

20120184554 - Therapeutic agent for mood disorders: Provided are an agent for the treatment and/or prophylaxis of a mood disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R1 represents aryl or the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.... Agent: Kyowa Hakko Kirin Co., Ltd.

20120184555 - Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the ergosterol biosynthesis: A composition comprising at least a pyridylethylbenzamide derivative of general formula (I) (a) and a compound capable of inhibiting the ergosterol biosynthesis (b) in a (a)/(b) weight ratio of from 0.01 to 20. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the phytopathogenic... Agent: Bayer Cropscience Ag

20120184556 - Substituted enzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators: Disclosed are substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators.... Agent:

20120184557 - Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently... Agent: Universite Paris Descartes

20120184558 - Crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine derivative: This invention provides novel crystalline acid salt forms of 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine, i.e. sitagliptin, to processes for their preparation and isolation, and to pharmaceutical compositions comprising the same.... Agent: Medichem S.a.

20120184559 - Novel compounds that are useful for improving pharmacokinetics: i

20120184560 - Molecular diagnostic methods for predicting brain metastasis of breast cancer: Disclosed are molecular diagnostic compositions and methods for predicting brain metastasis of breast cancer, as well as methods for drug repositioning to identify existing and new therapeutics for use in developing individualized, patient-specific treatment regimens for improving diagnoses and patient outcomes in individuals at risk for brain metastasis of breast... Agent: The Methodist Hospital Research Institute

20120184562 - 1,6- and 1,8-naphthyridines: s

20120184561 - Phenylacetamides suitable as protein kinase inhibitors: wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof; as well as their use, methods of use for them and methods of their synthesis, and the like. The compounds are protein kinase inhibitors and can,... Agent:

20120184563 - Composition for external application comprising aripiprazole and organic acid as active ingredients: [Summary] An external preparation formulation superior in the transdermal absorbability has been desired as a new administration route of aripiprazole. Transdermal absorption of aripiprazole has been enabled for the first time by appropriately combining aripiprazole and an organic acid (particularly fatty acid with low lipophilicity). That is, it has been... Agent: Medrx Co., Ltd.

20120184564 - Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea: u

20120184565 - Compounds for the reduction of beta-amyloid production:

20120184566 - Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof: Wherein n, R1, R2, R3, R4, R5 and R6 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as... Agent: Sanofi

20120184567 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120184569 - A3 adenosine receptor agonists and antagonists: as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20120184568 - Processes for preparing isoquinolinones and solid forms of isoquinolinones: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.... Agent:

20120184570 - Theophylline derivative inhibits osteoporosis: The theophylline derivative disclosed in the present invention is characterized by having the pharmaceutical functions of osteoporosis. The theophylline derivative protects against bone resorption and inflammatory mediator infiltration.... Agent: Kaohsiung Medical University

20120184571 - Quinazolinone derivatives useful as vanilloid antagonists: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a... Agent: Novartis Ag

20120184572 - Aryl gpr119 agonists and uses thereof: Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.... Agent: Metabolex, Inc.

20120184573 - process for the preparation of ambrisentan and novel intermediates thereof: The invention relates to improved processes for the preparation of ambrisentan. The invention also relates to a novel intermediate useful in the preparation of ambrisentan and a process for the preparation of the intermediate. The invention also relates to new polymorphic form of ambrisentan. In particular, it relates to a... Agent:

20120184574 - Indole derivatives and methods for antiviral treatment: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.... Agent: Ptc Therapeutics, Inc.

20120184575 - Topical administration carrier composition and therapeutic formulations comprising same: A topical administration carrier composition including water, glycerin and polysorbate, suitable for use in formulations with active ingredient compositions containing active ingredients such as minoxidil that are susceptible to systemic penetration, and solvents that are susceptible to evaporative loss, when the active ingredient composition is topically applied to the body.... Agent: Celmatrix Corporation

20120184576 - Antipsychotic agents and standardized antipsychotic fractions from rauwolfia tetraphylla and process of their isolation: The present invention relates to bioactive extracts its fractions and isolation of compound from Rauwolfia tetraphylla. The extracts and fractions are useful for the treatment of psychosis based on in-vivo validation on animal model and proportional binding affinities for dopaminergic-D2, Cholinergic (muscarinic) and Serotonergic (5HT2A) receptors for antipsychotic activity. The... Agent:

20120184577 - Pi3 kinase/mtor dual inhibitor: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.... Agent: Eli Lilly And Company

20120184578 - Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance: Compositions of hepatic therapeutic actives from one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid compounds. Also, methods for treating various liver diseases or certain cancers with such hepatic therapeutic actives, as well... Agent: Heptiva LLC

20120184579 - Quinolines and their therapeutic use: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms;... Agent:

20120184580 - Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof: Substituted di-arylhydantoin and di-arylthiohydantoins are provided and may find use as androgen receptor modulators. The compounds may find particular use in treating prostate cancer, including CRPC and/or hormone-sensitive prostate cancer.... Agent: Medivation Prostate Therapeutics, Inc.

20120184581 - Oligomer-opioid agonist conjugates: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20120184582 - Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same: The present invention relates to novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same.... Agent:

20120184583 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20120184584 - Methods and drug products for treating alzheimer's disease: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone.... Agent: Takeda Pharmaceutical Company Limited

20120184585 - Fatty acid niacin conjugates and their uses: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.... Agent: Catabasis Pharmaceuticals, Inc.

20120184586 - Desferrithiocin polyether analogues and uses thereof: Desferrithiocin analogues represents by the structural formulae described here, such as formula (I), are useful in treating conditions such as metal overload (e.g., iron overload from transfusion therapy), oxidative stress, and neoplastic and preneoplastic conditions.... Agent: University Of Florida Research Foundation, Inc.

20120184587 - Novel phenol derivative: Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of... Agent:

20120184588 - Compositions of dibromomalonamide and their use as biocides: A biocidal composition comprising 2,2-dibromomalonamide and an isothiazolinone-based biocide, and its use for the control of microorganisms in aqueous and water-containing systems.... Agent:

20120184589 - Pesticidal mixtures: The present invention relates to synergistic mixtures comprising, as active components one insecticidal compound I selected from the group of acrinathrin, allethrin, alpha-cypermethrin, beta-cypermethrin, bifenthrin, cycloprothrin, cyfluthrin, cypermethrin, cyphenothrin, deltamethrin, dimefluthrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, imiprothrin, permethrin, prallethrin, profluthrin, pyrethrin I, pyrethrin II, resmethrin, silafluofen, tau-fluvalinate, tetramethrin, theta-cypermethrin, tralomethrin,... Agent: Basf Se

20120184590 - Formulations of indole-3-carbinol derived antitumor agents with increased oral bioavailability: A pharmaceutical composition for treating, inhibiting, or preventing cancer can include an indole-3-carbinol derivative compound in a pharmaceutically acceptable carrier that is configured for oral administration. The indole-3-carbinol derivative compound can have antitumor activity, and oral administration can provide blood bioavailability of about 0.5% to about 25%. The pharmaceutically acceptable... Agent: University Of Kansas

20120184591 - Methods for treating prostatitis: It has been discovered that silodosin is effective in treating patients having symptoms associated with prostatitis with silodosin or a pharmaceutically acceptable salt thereof. In a preferred embodiment, patients are treated with 4 mg once daily.... Agent: Watson Pharmaceuticals, Inc.

20120184592 - Alkyl indole-3-carbinol-derived antitumor agents:

20120184593 - Laminin-332 production stimulating composition: Disclosed is a novel composition which has a function of stimulating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production stimulating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives and/or salts... Agent: Shiseido Company, Ltd

20120184594 - Phenylpyrrolidine compounds: This invention provides new phenylpyrrolidine compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.... Agent: Ferrer Internacional S.a.

20120184604 - Composition for the prevention or treatment of bone diseases comprising colforsin daropate: The present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases comprising colforsin daropate, and more particularly, the present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases such as bone fracture and osteoporosis, which inhibits osteoclast differentiation and bone... Agent: Korea Research Institute Of Chemical Technology

20120184605 - Methods and compositions for treating hiv-associated diarrhea: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In... Agent:

20120184606 - Neuraminidase inhibitor compounds, compositions and methods for the use thereof in anti-viral treatments: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.... Agent:

20120184607 - Use of piperphentonamine or salts thereof in manufacture of madicaments for prevention/treating brain diseases: The present invention relates to the use of piperphentonamine or pharmaceutically acceptable salts thereof to prevent/treat encephalopathy in mammals, and the use of a combination of piperphentonamine or pharmaceutically acceptable salts thereof and other medicines in manufacture a medicine to prevent/treat encephalopathy in mammals. The mammals include human beings, and... Agent:

20120184608 - N alkylcarbonyl amino lactone compounds and their use: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino lactone compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of alleviating the discomforts of irritation, itch, and... Agent:

20120184609 - Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a... Agent: Summa Health System

20120184610 - Methods and formulations for treating ineffective or decreased esophagal motility: Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated... Agent:

20120184611 - Selenoquinone-derived active organometallic complexes, methods for synthesizing same, and uses thereof: The present invention relates to the synthesis of novel biologically active selenoquinone-derived organometallic complexes, and to the uses thereof in the context of preventing or treating cancer.... Agent: Centre National De La Recherche Scientifique-cnrs-

20120184612 - Compositions and methods relating to carotenoids: A pet food composition having at least two carotenoids. The carotenoids can include a keto-carotenoid and at least one non-keto-carotenoid. The keto-carotenoid can include astaxanthin. The keto-carotenoid can include astaxanthin ester. The non-keto-carotenoid can include beta-carotene and/or lutein.... Agent:

20120184613 - Sulfur-containing compound and use thereof: wherein m represents 1, 2 or 3; n represents 0, 1 or 2; A represents an optionally substituted C2-C10 fluoroalkyl group; R1 represents an optionally halogenated C1-C4 chain hydrocarbon group, a halogen atom, or a hydrogen atom; R2 represents an optionally halogenated C1-C4 chain hydrocarbon group, etc.; R3 and R4... Agent: Sumitomo Chemical Company, Limited

20120184614 - N-alkylcarbonyl-amino acid ester compounds and their use for cough and pharyngitis: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino acid esters compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of reducing cough and pharyngeal irritation, itch,... Agent:

20120184615 - Stabilised prostaglandin composition: A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE1 analogue (e.g. misoprostol) in a solid polyurethane hydrogel. The polyurethane is either linear or cross-linked.... Agent:

20120184616 - Methods for treating inflammation: The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to... Agent:

20120184617 - Process for producing fingolimod salts: The invention relates to a process for producing pharmaceutically acceptable salts of fingolimod (I), comprising the step of reacting N-[1,1-bis hydroxymethyl-3-(4-octyl phenyl)-propyl]-acylamide (II) with an acidic compound. Furthermore, the invention provides different pharmaceutically acceptable salts of fingolimod and a polymorphic form of fingolimod hydrochloride.... Agent: Ratiopharm Gmbh

20120184618 - Teat dip concentrate: A concentrated iodine-free teat dip composition is provided including sulfonated oleic acid, a metal chelant, and an aqueous acidulant wherein the diluted use solution has a pH of less than 2.7. A method of treating mastitis is provided including applying the diluted concentrate on an animal's teats. Applying is accomplished... Agent: Ecolab Usa Inc.

20120184620 - Antioxidant composition: Disclosed is a stable and safe antioxidant composition which can be used routinely. Specifically disclosed is an antioxidant composition which contains one or more compounds selected from the group consisting of D-aspartic acid, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin... Agent: Shiseido Company, Ltd.

20120184619 - Composition for promoting collagen production: Disclosed is a novel composition which has an effect on promoting production of collagen. The composition has high photostability and is free from side effects such as those of retinoids. Specifically disclosed is a composition for promoting collagen production which contains one or more compounds selected from the group consisting... Agent: Shiseido Company, Ltd

20120184621 - Method for treating phytophotodermatitis: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.... Agent:

20120184622 - Composition for the treatment of cystic fibrosis: The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis... Agent: Scipharm Sarl

20120184623 - Amide derivatives of valproic acid and uses thereof: Amide derivatives of valproic acid are provided along their use in the treatment of epilepsy.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Lt.d

20120184624 - Treatment of alzheimer's disease: The present invention relates to a method of treating and/or preventing Alzheimer's disease and/or other tauopathies.... Agent:

20120184625 - Methods and compositions for controlling pests: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more β-diones, particularly β-diketones and β-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The... Agent: Bioprospect Limited

20120184626 - Germicidal topical compositions: A topical germicidal composition comprising: 50-85% wt. of an alcohol constituent comprising one or more C1-C4 monohydric alcohols; 0.01-5% wt. of a film forming constituent based-on one or more celluloses or cellulose derivatives, 0.01-25% wt. of a humectant, preferably glycerine; 0.01-5% wt. of an opacifier constituent; optionally but preferably a... Agent: Reckitt Benckiser LLC

20120184627 - Pharmaceutical composition: The invention concerns a co-processed additive for a solid-dose pharmaceutical composition, the additive comprising from about 50% to 99.5% by weight of at least one pharmaceutical compression aid and from about 0.5% to 50% by weight of at least one pharmaceutical lubricant, the melting point of said compression aid(s) being... Agent:

20120184628 - O/w type cosmetic composition with improved dosage form stability: The present invention relates to an O/W type cosmetic composition with improved formulation stability, and more particularly, to an O/W type cosmetic composition comprising a branched polymer having a lipophilic alkyl side chain and an anionic surfactant, as active ingredients for improving formulation stability.... Agent:

20120184629 - Cosmetic composition for massage: The present invention relates to a cosmetic composition for massage, and more particularly, to a cosmetic composition for massage that provides a smooth rolling sensation even with a low oil content by controlling the ratio and content of polar and nonpolar oils and properly penetrates into the skin according to... Agent:

20120184630 - Odour compounds: wherein R1 and R2 are independently selected from hydrogen, methyl, ethyl, propyl and isopropyl; or R1 and R2 together form a saturated or monounsaturated 5- or 6-membered hydrocarbon ring, as represented by the arcuate dotted line; R3 is selected from methyl and ethyl; R4 is selected from methyl, ethyl, propyl,... Agent:

  
07/12/2012 > 165 patent applications in 127 patent subcategories. category listing

20120178666 - Prodrugs of guanfacine: Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side... Agent: Shire LLC

20120178667 - Methods for treating septic shock: Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a... Agent: Oregon Health & Science University

20120178669 - Protease inhibitors, compositions and methods of use: This invention relates to grassystatins A, B and C, and their isolated or purified forms. The compounds of the invention are useful as aspartic protease, gamma secretase, or metalloprotease inhibitors. Methods of using the compounds and compositions thereof are also disclosed.... Agent: University Of Florida Research Foundation, Inc.

20120178668 - Proteinaceous compounds and uses therefor: The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth... Agent: The University Of Queensland

20120178670 - Acylated glucagon analogues: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the... Agent: Zealand Pharma A/s

20120178671 - Inhibition of nfk-b mediated virus replication with specific oligosaccharides: The inventors surprisingly found that specific oligosaccharides are capable of inhibiting viral replication through inhibiting NF-κB activation. The invention thus pertains to a composition comprising pectin (in the form of digalacturonic acid, trigalacturonic acid, polygalacturonic acid), Arabinoxylan from rice bran, β-glucan from bakers yeast, D-Ribose or mixtures there-of for inhibiting... Agent: N.v. Nutricia

20120178672 - Compositions and methods for sparing muscle in renal insufficiency and during hemodialysis: A nutritional composition and method of use that improves the net balance in skeletal muscle by targeting both the synthetic and breakdown processes. The disclosed composition provides for improved protein intake to increase skeletal muscle protein accretion in stressed patients who are at risk for the development of renal insufficiency... Agent:

20120178673 - Fat accumulation suppressor: A fat accumulation suppressor comprising as an active ingredient a whey protein hydrolysate is provided. The hydrolysate has a molecular weight range of no higher than 10 kDa and a main peak of molecular weight at 200 Da to 3 kDa; an APL (average peptide chain length) of 2 to... Agent: Megmilk Snow Brand Co., Ltd.

20120178674 - Mixture of non-digestible oligosaccharides for stimulating the immune system: Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.... Agent: N.v. Nutricia

20120178675 - Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin: Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of rapid acting injectable insulin formulations are described herein. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”) and a dissolution/stabilization agent, and optionally... Agent: Biodel Inc.

20120178681 - Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment: Bipiperidinyl compounds of the formula I, are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.... Agent: Merck Sharp & Dohme Corp.

20120178678 - Derivatives of 2h pyridazin- 3 -ones, their preparation and their use as scd-1 inhibitors: The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: —R1 represents one or more groups such as: trifluoromethyl, halogen such as F, Cl, —when n=m=1, W represents CH then Y represents oxygen, —U represents: either —(C═O)CH2NH— and is branched at position 4... Agent: Pierre Fabre Medicament

20120178679 - Fused aromatic ptp-ib inhibitors: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.... Agent: Kaneq Pharma Inc.

20120178680 - Glycoside derivatives and uses thereof: e

20120178676 - Pegylated c-peptide: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.... Agent: Cebix, Inc.

20120178677 - Soft protease inhibitors, and pro-soft forms thereof: The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase... Agent: Trustees Of Tufts College

20120178682 - Gb1 peptidic compounds and methods for making and using the same: GB1 peptidic compounds that specifically bind to a target molecule are provided. Also provided are methods for making and using the compounds. These compounds and methods find use in a variety of applications in which specific binding to target molecules, e.g., target proteins, is desired.... Agent:

20120178683 - Vegf antagonist formulations: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc.

20120178684 - Surgical calcium phosphate citrate-containing cement and method of manufacturing the same: The present invention discloses a surgical cement and a manufacturing method thereof. The surgical cement comprises a cementing component selected form the group of a basic calcium phosphate consisting of tetracalcium phosphate, alpha-tricalcium phosphate, decomposed hydroxyapatite, or a combination thereof; a setting reagent selected form the group of an acidic... Agent: Maxigen Biotech Inc.

20120178685 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20120178686 - Chemical induction of lactation: The present invention describes a method of inducing lactation in non-human mammals by using a single administrations of an estrogen compound, a dopaminergic antagonist, and oxytocin. For example, the estrogen compound may be a long acting composition and is administered at least one week before the dopaminergic antagonist. However, the... Agent:

20120178687 - Suspension formulations of insulinotropic peptides and uses thereof: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic... Agent: Intarcia Therapeutics, Inc.

20120178688 - Therapeutic agents for reducing parathyroid hormone levels: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds... Agent: Kai Pharmaceuticals, Inc.

20120178689 - Methods of treatment with natriuretic peptides: Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.... Agent:

20120178690 - Novel netrin derivatives and uses thereof: Netrin proteins and their receptors regulate cell and axon migration, and are implicated in tissue morphogenesis, tumorigenesis and angiogenesis. Deregulation of mechanisms that control cell motility plays a key role in tumor progression by promoting tumor cell dissemination. Unwanted neovascularization also contributes to tumor progression and metastasis and to ocular... Agent: The Royal Institution For The Advancement Of Learning/mcgill University

20120178692 - Dosage forms of polymer-factor viii moiety conjugates: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.... Agent: Nektar Therapeutics

20120178691 - Factor viii compositions and methods of making and using same: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.... Agent: Amunix Operating Inc.

20120178693 - Cofactors for thrombin activation of factor vii and uses thereof: The invention relates to fusion proteins that bind the enzyme thrombin and enhance the activation of the substrate Factor VII to the product Factor VIIa. The invention is also directed to polynucleotides, vectors, host cells, pharmaceutical compositions, and methods of treatment.... Agent: Bayer Healthcare LLC

20120178694 - Modified compstatin with peptide backbone and c-terminal modifications: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.... Agent:

20120178695 - Methods of treating neuropathic pain: The disclosure relates, at least in part, to methods of treating neuropathic pain in a patient in need thereof by administering an effective amount of a disclosed compound, e.g. a peptide NMDA receptor partial agonist.... Agent:

20120178696 - Compositions and methods for modulating ampa receptor-mediated excitotoxicity: The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT1-3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1) or the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting... Agent: Centre For Addiction And Mental Health

20120178698 - Agents and uses thereof: The present invention provides agents capable of activating Sox11 for use in medicine. In particular, the agents of the invention are useful in the treatment of cancers, such as lymphomas (e.g. mantel cell lymphoma). The invention further provides pharmaceutical compositions of the agents of the invention, as well as methods... Agent:

20120178697 - Compositions and methods for the inhibition of dishevelled proteins: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ... Agent:

20120178699 - Klotho protein and related compounds for the treatment and diagnosis of cancer: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.... Agent: Tel Hashomer Medical Research Infrastructure And Services Ltd.

20120178700 - Peptidomimetic macrocycles: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.... Agent: Aileron Therapeutics, Inc.

20120178701 - Melanocortin receptor-specific peptides: e

20120178702 - Stable lipid-comprising drug delivery complexes and methods for their production: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention... Agent: University Of Pittsburgh

20120178703 - Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof: v

20120178706 - Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside: The invention concerns an extract of Centella asiatica comprising more than 75 wt. % of a mixture of madecassoside, terminoloside and asiaticoside, relative to the extract total weight, an extract of Centella asiatica comprising more than 95 wt. % of a mixture of madecassoside and terminoloside relative to the extract... Agent: Bayer Consumer Care Ag

20120178705 - Methods for preparation of glycosphingolipids and uses thereof: Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.... Agent: National Taiwan University

20120178704 - Prevention and treatment of colon cancer: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.... Agent:

20120178707 - Methods for treating prostrate conditions: Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound... Agent:

20120178708 - Phenethylsulfone isoindoline derivatives and their use: Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.... Agent: Celgene Corporation

20120178709 - Crystalline phases of 5,6-dfichloro-2-(isopropylamino)-1-ß-l-ribofuranosyl)-1h-benzimidazole: The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.... Agent:

20120178792 - Drg11-responsive (dragon) gene family: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.... Agent: The General Hospital Corporation

20120178791 - Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212): The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-I. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV... Agent: University Of Massachusetts

20120178793 - Nucleotide-cochleate compositions and methods of use: The present invention is directed to cochleate composition that include a nucleotide. The nucleotide may generally be bound via a linker to a component of the cochleate, or to a lipophilic tail. Additionally or alternatively, the nucleotide may he associated with a transfection agent. The present invention also includes methods... Agent: Biodelivery Sciences International, Inc.

20120178795 - Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.... Agent: Novartis Ag

20120178794 - Rnai-mediated inhibition of rho kinase for treatment of ocular disorders: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.... Agent: Alcon Research, Ltd.

20120178796 - Splice variants: We disclose the isolation and characterization of sirtuin 1 [SIRT1] splice variants.... Agent:

20120178797 - Novel therapeutic and diagnostic products and methods: The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the... Agent:

20120178710 - Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof: The invention provides methods for the synthesis of cyclic dinucleotides and thiophosphate analogs thereof as well as a new family of analogs of cyclic diguanosine monophosphate that includes a series of seven phosphorothioate derivatives that includes diastereomers of mono-, di-, and trithiophosphates.... Agent: Rutgers, The State University Of New Jersey

20120178711 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from... Agent: Cerulean Pharma Inc.

20120178712 - Phytochemical compositions including sesamin for anti-inflammatory, anti-cytokine storm, and other uses: A composition (e.g., phytochemical composition) including sesamin, the composition exhibiting anti-inflammatory, anti-cytokine storm, connective tissue preservation, anti-viral, and/or other properties in biological tissue. The phytochemical composition therapeutically affects a pro-inflammatory cytokine condition, for instance facilitating or effectuating decrease in a quantity of a pro-inflammatory cytokine, for example, interleukin-1 and tumor... Agent: Thailand Excellence Center Of Tissue Engineering

20120178713 - Phenyl sulphonamides as modulators of ion channels: The present invention relates to phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.... Agent: Vertex Pharmaceuticals Incorporated

20120178714 - Phosphorus-containing compounds & uses thereof: e

20120178715 - Substituted pyrazolo[1,5-a]pyrimidine compounds as mtor inhibitors: Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.... Agent: Array Biopharma Inc.

20120178716 - Unsaturated heterocyclic derivatives: m

20120178717 - 4-quinolinemethanols as anti-malarial agents: The present invention relates to substituted 4-qinolinemethanols and pharmaceutical compositions thereof and methods of using the same for treating of malaria, tuberculosis, and other infectious diseases.... Agent: Jenrin Discovery

20120178718 - Novel imidazolidine compounds as androgen receptor modulators: wherein X, R1, R2a, R2b, R2c, R3aR3b, R4a, R4b, R4c, and m1 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cachexia, osteoporosis,... Agent:

20120178719 - Modulation of phospholipase d for the treatment of neurodegenerative disorders: The present invention relates to methods of treating neurodegenerative diseases comprising administering, to a subject in need of such treatment, one or more agent that inhibits or reduces the action, including the catalytic activity, of an enzyme of the phospholipase D family, such as phospholipase D1 and/or phospholipase D2. The... Agent: The Trustees Of Columbia University In The City Of New York

20120178720 - Bisphosphonates as inhibitors of acid sphingomyelinase: The present invention refers to bisphosphonate and phosphonate/phosphate compounds of Formulae I and its use as inhibitors of aSMase enzyme activity.... Agent:

20120178721 - Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines: —R1 and R2 each designate an acyl group derived from a saturated or unsaturated, straight-or branched-chain carboxylic acid having from 2 to 18 carbon atoms, which is unsubstituted or bears one to three substituents selected among hydroxyl, dihydroxyphosphoryloxy, alkyl of 2 to 18 carbon atoms, alkoxy of 2 to 18... Agent: Om Pharma

20120178722 - Synergistic antimicrobial composition: A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride.... Agent:

20120178723 - Heteroaryls and uses thereof: s

20120178724 - Compositions for reducing the incidence of drug induced arrhythmia: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics,... Agent: Warner Chilcott Company, LLC

20120178725 - Method of modulating ship activity: A method of treating or preventing an immune disorder, such as graft versus host disease, in a subject. The method includes the administering a SHIP1 inhibitor, such as 3α-aminocholestane, to a subject in need of treatment. Thus, SHIP1 inhibitors taught herein represent a novel class of small molecules that have... Agent: H. Lee Moffitt Cancer And Research Institute, Inc.

20120178727 - Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic: The present invention relates to a topical pharmaceutical composition that comprises the combination of an antimicrobial, a glucocorticoid, an antimycotic and pharmaceutically acceptable vehicles or excipients; the method for producing the composition and the use of said composition for treating localized dermatosis ailments.... Agent:

20120178726 - Novel compounds: e

20120178728 - Use of a copolymer in the form of a solubiliser for a poorly water-soluble compound:

20120178729 - Crystalline form i rosuvastatin zinc salt: The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.... Agent:

20120178730 - Sod-imitating metal complexes: The present invention comprises a process to synthesise metal complexes from macrocyclic polyazapyridinophane compounds characterised as superoxide dismutase enzyme (SOD) mimetics. Furthermore, the present invention relates to the macrocyclic polyazapyridinophane compounds themselves, the metal complexes formed from these and to their use in the treatment of diseases the aetiology of... Agent: Universitat De Valencia

20120178731 - Nasal, wound and skin formulations and methods for control of antibiotic-resistant staphylococci and other gram-positive bacteria: Formulations and methods are disclosed which are effective to kill or control bacteria in the nares including gram-positive bacteria strains of S. aureus that are antibiotic resistant (MRSA—methicillin-resistant Staphylococcus aureus. A preferred composition comprises one or more medium-chain alcohols (dodecanol), glycerol monoesters (glycerol monocaprylate or glycerol monolaurate), and/or benzoic acid... Agent:

20120178732 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease: The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent:

20120178735 - 2h-chromene compound and derivative thereof: Provided is a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action. The 2H-chromene compound or derivative is particularly useful for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.... Agent: Astellas Pharma Inc.

20120178736 - Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use: Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are... Agent:

20120178734 - Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-carboxylic acid amides: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.... Agent: Boehringer Ingelheim International Gmbh

20120178733 - Factor xa inhibitors: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat... Agent: Millennium Pharmaceuticals, Inc.

20120178737 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N-(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is... Agent:

20120178738 - Dibenzo [b,f] [1,4]oxazapine compounds: where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD,... Agent: Aryx Therapeutics, Inc.

20120178739 - Lactam compounds useful as protein kinase inhibitors: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20120178740 - Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors: The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase... Agent: Leo Pharma A/s

20120178741 - Sulfonylamino-derivatives as novel inhibitors of histone deacetylase: e

20120178742 - Metabotropic glutamate receptor modulators: The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.... Agent: Merz Pharma Gmbh & Co. Kgaa

20120178743 - Novel adenine compound and use thereof: [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120178744 - Fused tricyclic compounds as novel mtor inhibitors: The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.... Agent:

20120178746 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention... Agent: Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International Gmbh

20120178745 - Novel crystalline oxazine derivative: The invention relates to 5-cyano-3-methyl-pyridine-2-carboxylic acid [3-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-4-fluoro-phenyl]-amide in crystalline form, to its preparation, its medical use and to medicaments comprising said compound in crystalline form.... Agent:

20120178747 - Compositions and methods for bone formation and remodeling: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated... Agent:

20120178748 - Heteroaryl compounds and methods of use thereof: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g.,... Agent: Sunovion Pharmaceuticals Inc.

20120178750 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: o

20120178749 - Ns1 protein inhibitors: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such... Agent:

20120178751 - 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives: e

20120178752 - Rho kinase inhibitors:

20120178754 - Furazano '3, 4-b! pyrazines and their use as anti-tumor agents: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not... Agent: Compass Pharmaceuticals LLC

20120178753 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120178755 - Cyanoisoquinoline compounds and methods of use thereof: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:... Agent: Fibrogen, Inc.

20120178756 - Compounds useful as inhibitors of atr kinase: e

20120178757 - Method for the prevention of cancer metastasis: A method is provided for the prevention of cancer metastasis in a patient comprising administering an adrenergic receptor antagonist to a patient in need thereof. The invention also includes an adrenergic receptor antagonist for use in the prevention of tumour recurrence in a patient. Also provided is a kit of... Agent: Nottingham University Hospitals Nhs Trust

20120178758 - Styryl-triazine derivatives and their therapeutical applications: The invention provides Styryl-Triazine derivatives, and further provides methods of using these compounds to modulate protein kinases and to treat protein kinase mediated diseases.... Agent: California Capital Equity, LLC

20120178759 - Condensed pyridine derivatives useful as potent inhibitors of the protein kinase ck2: The invention relates to the use of specific compounds of formula (I) and their pharmaceutically-acceptable salts: (Formula 1) (I) as a new family of protein kinase CK2 inhibitors; the invention also relates to the use of compounds of formula (I) for the preparation of pharmaceutical compositions for the prevention and/or... Agent: Institut Nat De La San Et De La Rech Med (inserm)

20120178760 - Heterocyclic-fused pyrazolo[4,3-c] pyridin-3-one m1 receptor positive allosteric modulators: The present invention is directed to heterocyclic fused pyrazole[4,3-c]pyridine-3-one compounds of formula (I): which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed... Agent:

20120178761 - Pyrrolidine derivatives: e

20120178762 - Compositions of azimilide dihydrochloride: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.... Agent: Warner Chilcott Company, LLC

20120178763 - Method of treating anxious major depressive disorder: The invention is directed to using 4-{(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, or enantiomer thereof, or pharmaceutically acceptable salt thereof, and/or mixture thereof to treat anxious major depressive disorder (AMDD).... Agent:

20120178764 - Novel compounds: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.... Agent:

20120178765 - Novel glucokinase activators and processes for the preparation thereof: The present invention provides an amide derivative having a stilbene or 1,2-diphenylethane moiety within the molecule thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The amide derivative of the present invention activates glucokinase remarkably, and therefore they can be usefully applied for treating glucokinase-mediated... Agent: Yuhan Corporation

20120178766 - Furopyrimidinedione derivatives as trpai modulators: The present invention is related to novel furopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds... Agent:

20120178767 - Treatment of liver disorders with p13k inhibitors: The invention provides methods to treat certain liver disorders by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific compounds useful for these methods and ways to identify subjects who are particularly suitable for receiving these treatments.... Agent: Gilead Calistoga LLC

20120178768 - Phosphodiesterase inhibitor treatment: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.... Agent:

20120178769 - Novel compounds for inhibiting eef-2 kinase activity: The present invention discloses novel compounds for inhibiting eEF2 kinase and methods of use thereof.... Agent: The University Of Medicine And Dentistry

20120178770 - Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors: Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.... Agent: Nerviano Medical Sciences S.r.l.

20120178772 - Compositions comprising enzyme-cleavable oxycodone prodrug: The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with... Agent:

20120178773 - Compositions comprising enzyme-cleavable oxycodone prodrug: The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the \compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with... Agent:

20120178771 - Oral pharmaceutical compositions of buprenorphine and method of use: The present invention is directed to oral, therapeutically effective pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof, including delayed onset and controlled release dosage forms. The present invention is also directed delayed onset, rapid release dosage forms and delayed onset, extended release dosage forms of... Agent:

20120178774 - Toll-like receptor modulators and uses thereof: e

20120178775 - Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (ftld-u): Methods for rescuing learning, memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are disclosed. The method comprises: a) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer; b) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms... Agent: Academia Sinica

20120178776 - Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mglur5 modulators: In one aspect, the invention relates to dihydronaphthyridinyl(organo)methanone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with... Agent:

20120178777 - Medicaments for inhibiting thrombus formation: A Medicaments for inhibiting thrombus formation contains active ingredients which are triflusal and clopidogrel bisulfate, wherein a mass ratio of triflusal to clopidogrel bisulfate is (100-650):(30-150), preferably (1-20):1, more preferably (3-6):1, and even more preferably 3:1 or 6:1.... Agent: Guizhou Liansheng Parmaceutical Co., Ltd.

20120178779 - Fused heterocyclic compound and use thereof: M

20120178778 - Pyrazolopyridines: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120178780 - Raf kinase inhibitors: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.... Agent:

20120178781 - Kappa opioid receptor ligands: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.... Agent: Research Triangle Institute

20120178782 - Compositions and methods for treating proliferative diseases: Synergistic pharmaceutical compositions and the methods for preventing and treating proliferative diseases such as cancer and psoriasis. The compositions comprise synergistic combinations of: (i) an acyl-CoA-synthetase enzyme inhibitor (AcsI4), (ii) a compound having an inhibiting effect on enzymes with cyclooxygenase activity (COX); and (iii) a compound selected from a 5-lypoxygenase... Agent:

20120178783 - Hdac inhibitors: n

20120178784 - Use of inhibitors of the renin-angiotensin system: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and... Agent:

20120178785 - Derivatives of n-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators: Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.... Agent: Ramot At Tel-aviv University Ltd.

20120178786 - Use of tetramic acid derivatives for controlling pests by drenching, drip application, or dip application: Compounds of the formula (I) in which A, B, G, W, X, Y and Z can have the meanings given in the description are highly suitable for controlling animal pests such as insects and/or spider mites and/or nematodes by treating the soil/growth substrate by drenching or drip application or dipping... Agent:

20120178787 - Melatonin and its use in preventing postoperative complications: The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture... Agent:

20120178788 - Method for suppressing esterification of pharmaceutical composition: Disclosed are a pharmaceutical composition for external application, an adhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingredient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch... Agent: Nipro Patch Co., Ltd

20120178789 - Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use: The present invention relates to compounds of the general formula: (I) wherein ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment... Agent:

20120178790 - Crystalline form of a 3-phenoxymethylpyrrolidine compound: The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.... Agent: Theravance, Inc.

20120178798 - Substituted cyclopentanes having prostaglandin activity: e

20120178799 - Energy beverage with creatine and caffeine combination: The present invention is an energy drink that included both creatine and caffeine, which provides superior energy, concentration and performance over other energy beverages/liquids. The invention can include other vitamins and beneficial additives, but is intended to be unflavored and unsweetened.... Agent:

20120178800 - Synergistic antimicrobial composition: A synergistic antimicrobial composition having two components. The first component is glutaraldehyde. The second component is 2,6-dimethyl-1,3-dioxan-4-yl acetate.... Agent:

20120178801 - Compositions and its use in treating obesity or inducing weight loss: The present invention provides a composition comprising polyisoprenylated benzophenone derivative and at least one component selected from stilbene derivative and anthocyanins. The composition inhibits adipogenesis and is therefore useful in treating obesity or weight loss.... Agent:

20120178802 - 2,3-fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals: Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The therapeutic effect is achieved via inhibition of viral neuraminidases, also known as viral sialidases. These neuraminidases are classified under... Agent:

20120178803 - Method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells: Provided is a method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester... Agent: China Medical University

20120178804 - Nitrogen-containing inorganic carrier materials: The invention relates to nitrogen-containing inorganic carrier materials, more particularly to inorganic carrier materials containing organically bonded nitrogen, to their preparation and also to their use for stabilizing iodine-containing compounds, and also to binder formulations comprising them and to the use thereof for protecting industrial materials.... Agent: Lanxess Deutschland Gmbh

20120178805 - Phenolic hydrazone macrophage migration inhibitory factor inhibitors: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal... Agent:

20120178806 - Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle: Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.... Agent: Qlt Inc.

20120178807 - Method of controlling harmful arthropod, composition, and electrostatic spray device: A method of the present invention, for controlling a harmful arthropod employs an ester compound which has a specific structure. Accordingly, with the method of the present invention, it is possible to control a wide variety of harmful arthropods effectively, without carrying out any heating process (e.g., a smoking process)... Agent: Sumitomo Chemical Company, Limited

20120178808 - Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form... Agent:

20120178809 - Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof: f

20120178810 - Extended release formulation of an antiepileptic agent: The present invention relates to an extended release formulation of an antiepileptic agent. More particularly, the present invention relates to an extended release formulation of divalproex sodium. The present invention also relates to a process for the preparation of extended release formulation of divalproex sodium.... Agent:

20120178811 - Method of using beta-hydroxy-beta-methylbutyrate to reduce the risk of infection in an elderly individual: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of β-hydroxy-β-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to... Agent: Abbott Laboratories

20120178812 - Pharmaceutical formulations containing lipoic acid derivatives: Pharmaceutical formulations containing lipoic acid derivatives are made.... Agent:

20120178813 - Lipid-lowering antidiabetic agent: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.... Agent: Thetis Pharmaceuticals LLC

20120178814 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent:

20120178815 - Compositions of (-)-e-10-oh-nt and methods for their synthesis and use: This present disclosure provides compositions comprising E-10-OH-NT metabolites of AT and NT, methods for their synthesis and methods for their use.... Agent: Adolor Corporation

20120178816 - Carbamide peroxide treatments for the reproductive tract: Disclosed are methods of maintaining fertility or treating retained placenta, reproductive tract infection, or reproductive tract inflammation in an animal by administering carbamide peroxide to the reproductive tract of the animal. The carbamide peroxide administration removes placental remains on the uterine wall, protects against or treats reproductive tract infection, and... Agent:

20120178817 - Compositions of dibromomalonamide and their use as biocides: A biocidal composition comprising 2,2-dibromomalonamide and a surface active biocide, and its use for the control of microorganisms in aqueous and water-containing systems.... Agent:

20120178818 - Compositions of dibromomalonamide and their use as biocides: A biocidal composition comprising 2,2-dibromomalonamide and sodium ortho-phenylphenol, and its use for the control of microorganisms in aqueous and water-containing systems.... Agent:

20120178819 - Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging: Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic... Agent: Lithera, Inc.

20120178820 - Method for treating arthritis: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen,... Agent: Anamar Ab

20120178821 - Polymorphic form of toremifene citrate and process for its preparation: The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts.... Agent: Ranbaxy Laboratories Limited

20120178822 - Co-processed excipient compositions: An oral solid dosage form having improved dissolution profile and a method of producing the same are provided. The present invention particularly provides a co-processed excipient composition and a method of producing the same. More particularly, it relates to a co-processed binary mixture of crosslinked polyvinylpyrrolidone and calcium silicate; wherein... Agent: Isp Investments Inc.

20120178823 - Gel-like composition: in a content of from 0.1 to 20 percent by weight; an aqueous component in a content of 0.65 to 1.5 times by weight relative to the content of the polyglycerol alkyl ether; and an oily component in a content of from 50 to 99.835 percent by weight.... Agent:

20120178824 - Hydrogels based on esters of polyisobutenesuccinic acid: The present invention relates to the use of esters of polyisobutenesuccinic acid for producing hydrogels, and to the use of such hydrogels for cleaners and care compositions for the home (so-called homecare products), for cosmetics, and also for medical products.... Agent: Basf Se

20120178825 - Cyclohexanedimethanol-based hydrophilic polyurethane urea: The invention relates to novel polyurethane ureas which can be used in the production of hydrophilic coatings on various substrates.... Agent: Bayer Materialscience Ag

20120178826 - Wound dressing compositions suitable for use in negative pressure wound therapy: The present invention relates to a wound dressing composition suitable for use in a negative pressure wound therapy application comprising hydrocolloids, hot melt acrylic adhesives, tackifiers, elastomeric binders, and extenders, and if desired, active ingredients.... Agent:

20120178827 - Solid pharmaceutical preparations comprising amphiphilic copolymers on the basis of polyethers in combination with surfactants: Dosage forms comprising formulations of sparingly water-soluble active ingredients in a polymer matrix composed of polyether copolymers, said polyether copolymers being obtained by free-radically initiated polymerization of a mixture of 30 to 80% by weight of N-vinyllactam, 10 to 50% by weight of vinyl acetate and 10 to 50% by... Agent: Basf Se

20120178828 - Process for the preparation of a flavoring concentrate, and a flavoring concentrate: The present invention relates to processes for the preparation of a flavoring concentrate, to a flavoring concentrate which can be prepared by a process according to the invention, to products comprising one or more flavoring concentrates according to the invention, and to processes for the concentration of flavoring and/or aromatic... Agent: Symrise Ag

20120178829 - Bi - or tricyclic sterically hindered alkoxyamines and process for their preparation: The instant invention pertains to novel bi- or tricyclic sterically hindered alkoxyamines, their precursors, a process for their preparation and their use as light stabilizers for polymers or coatings, as flame retardants, as peroxide substitutes (rheology modifiers) or carbon radical scavengers.... Agent: Basf Se

20120178830 - Liquid composition to be filled in soft capsules: Disclosed is a liquid composition which is intended to be filled in soft capsules and comprises an oil-insoluble ingredient dispersed in an edible oil, a reactive monoglyceride, and a triglycerol fatty acid ester having a monoester content of 50% or more. The liquid composition to be filled in soft capsules... Agent: Riken Vitamin Co., Ltd.

  
07/05/2012 > 175 patent applications in 135 patent subcategories. category listing

20120172284 - Isozyme-specific antagonists of protein kinase c: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120172283 - Methods and compositions for targeted drug delivery: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy.... Agent:

20120172285 - Methods and compositions for specific modulation of mcl-1: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic... Agent:

20120172286 - Therapeutic use for alpha1 proteinase inhibitor in hematopoiesis: A previously unrecognized fundamental property of α1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or... Agent: Institute For Human Genetics And Biochemistry

20120172287 - Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present... Agent: Anges Mg, Inc.

20120172288 - Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions: The present disclosure relates to the use of nutritional compositions including lactoferrin produced by a non-human source in supporting resistance to diseases or conditions caused by bacterial and viral pathogens.... Agent:

20120172289 - Multifunctional glycopeptide antibiotic derivatives for fluorescent imaging and photoactive antimicrobial therapy: The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection.... Agent: Nanyang Technological University

20120172290 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Abbott Laboratories

20120172291 - Macrocyclic hepatitis c serine protease inhibitors: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or... Agent:

20120172292 - Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide: This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO scavenger.... Agent: New York University

20120172293 - Peptide and use thereof: i

20120172294 - Treatment of diseases: The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing... Agent: Dmi Acquisition Corp.

20120172295 - Gip receptor-active glucagon compounds: Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.... Agent: Indiana University Research And Technology Corp

20120172296 - Water-soluble aie luminogen for monitoring and retardation of amyloid fibrillation of insulin: The presently described subject matter is directed to a water-soluble conjugated polyene compound and the derivatives thereof that exhibit aggregation induced emission, as well as any water dispersible, fluorescent, polymeric microparticles, nanoparticles, and/or pharmaceutical composition comprising the water-soluble conjugated polyene compound and/or the derivatives thereof. Also provided are methods of... Agent: The Hong Kong University Of Science And Technology

20120172297 - Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases: Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease,... Agent:

20120172298 - Glp-1 and fgf21 combinations for treatment of diabetes type 2: The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1... Agent: Novo Nordisk A/s

20120172299 - Purification of erythropoietin: In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing Calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a... Agent: F. Hoffmann-la Roche Ag

20120172300 - Remodeling and glycopegylation of fibroblast growth factor (fgf): The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed.... Agent: Novo Nordisk A/s

20120172301 - Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ace2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling: The present invention relates to a pharmaceutical composition comprising an effective amount of angiotensin-(1-9) or derivatives thereof, and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Additionally, the present invention describes the use of the pharmaceutical composition and the angiotensin-(1-9) peptide or peptides derived thereof which are... Agent:

20120172302 - Composition for the treatment of benign prostate hyperplasia: The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof.... Agent:

20120172303 - Growth hormones with prolonged in-vivo efficacy: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.... Agent: Novo Nordisk Health Care Ag

20120172304 - Intranasal carbetocin formulations and methods for the treatment of autism: Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors,... Agent:

20120172305 - Retro-inverso peptides derived from interleukin-6: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the... Agent: Myelos Corporation

20120172307 - Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents: Disclosed are methods of reducing the incidence of oxidative stress in infants, toddlers, and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory diseases.... Agent: Abbott Laboratories

20120172306 - Use of hasf as a protective agent against ischemic tissue damage: A method of inducing a protective response against ischemic tissue damage is carried out by administering to subject a composition comprising an HASF polypeptide. The composition is administered prior to an ischemic event such as myocardial infarction to reduce tissue damage associated with such an event.... Agent: Duke University

20120172308 - Oligopeptides and their use in cosmetics: The present invention relates to the cosmetic use of oligopeptides, cosmetic preparations which comprise such oligopeptides as well as certain oligopeptide derivatives themselves.... Agent: Cognis France S.a.s.

20120172309 - Transglutaminase-activating peptide and cosmetic or pharmaceutial composition containing same: The present invention also relates to the use of a composition containing the peptide of general formula (I) as an active ingredient which activates human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation. The invention also relates to a cosmetic treatment method for preventing... Agent:

20120172310 - Soluble guanylyl cyclase a1 and a-8r peptide as diagnostic markers of and therapeutic targets for prostate cancer: The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.... Agent: University Of Toledo

20120172311 - Peptidomimetic macrocycles: The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides.... Agent: Aileron Therapeutics, Inc.

20120172312 - Muc-1 cytoplasmic domain peptides as inhibitors of cancer: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.... Agent:

20120172314 - Klotho protein and related compounds for the treatment and diagnosis of cancer: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.... Agent: Cedars-sinai Medical Center

20120172313 - Treatment of proliferative diseases: The present invention relates to methods for preventing or treating proliferative diseases. In particular, the present invention relates to the use of compositions derived or derivable from plants, such as plant defensins, particularly in methods for the prevention or treatment of proliferative diseases such as cancer. The present invention also... Agent:

20120172315 - Peptides used for treating cancers and, in particular, chronic lymphoid leukaemia: The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia.... Agent:

20120172316 - Cloning, yeast expression, purification and biological activity of the extension region of the soybean 7s globulin alfa' subunit involved in hep g2 cell cholesterol homeostasis: A truncated form of α′ chain (eα′), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the... Agent: Indena S.p.a.

20120172317 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.

20120172318 - Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin f2alpha receptor: The invention relates to compositions which are useful for inhibiting prostaglandin F2α receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.... Agent: Theratechnologies, Inc.

20120172319 - Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides: Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.... Agent: Abbott Laboratories

20120172320 - Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2: Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.... Agent:

20120172321 - Hsp90 inhibitors: a

20120172322 - Methods of controlling insects: Methods of controlling insects include applying at least one spinosyn compound to a locus of a neonicotinoid-resistant insect, such as a strain of Drosophila melanogaster resistant to a neonicotinoid compound. The spinosyn compound may be a mixture of spinosyn A and spinosyn D. The spinosyn compound may cause up to... Agent: Dow Agrosciences LLC

20120172323 - Methods for treating malaria, tuberculosis and mac diseases: Described herein are formulations and methods for treating diseases caused by infectious pathogens, including mycobacterium avium complex, mycobacterium tuberculosis, Nocardia, Plasmodium falcium, and Plasmodium berghei.... Agent: Cempra Pharmaceuticals, Inc.

20120172414 - Bicyclic cyclohexose nucleic acid analogs: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.... Agent: Isis Pharmaceuticals, Inc.

20120172415 - Exon skipping therapy for functional amelioration of semifunctional dystrophin in becker and duchenne muscular dystrophy: Methods for stabilizing unstable proteins or for restoring functionality to non-functional or poorly functioning (semi-functional) proteins using exon skipping technology are provided. The methods involve the administration of antisense oligonucleotides to cause exon skipping, thereby removing one or more exons responsible for protein instability or lack of functionality. For example,... Agent:

20120172412 - In vivo polynucleotide delivery conjugates having enzyme sensitive linkages: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate... Agent: Arrowhead Madison Inc.

20120172413 - Increasing lifespan by modulating crtc expression or localization, and methods of screening for modulators of same: The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to CRTC modulation. In certain embodiments, the invention provides compositions and methods for enhancing longevity in an organism by inhibiting CRTC activity, such as, for example, inhibiting CRTC expression or cellular localization... Agent: The Salk Institute For Biological Studies

20120172416 - Method for the preparation of micro-rna and its therapeutic application: The present invention relates to compositions comprising a therapeutically effective amount of miRNAs, their use for the treatment of medical conditions benefiting from being treated with these compositions, as well as methods for the preparation of compositions comprising miRNAs.... Agent:

20120172409 - Methods and kits for linking polymorphic sequences to expanded repeat mutations: Methods and kits are provided for determining which single nucleotide polymorphism (“SNP”) variant of an allele of a heterozygous patient is on the same allele as a disease-causing mutation. Also, provided are kits for multi-SNP diagnosis and treatment, targeting combinations of SNPs having greater joint prevalence of heterozygosity in Huntington's... Agent: Medtronic, Inc.

20120172411 - Novel trialkyl cationic lipids and methods of use thereof: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present... Agent: Protiva Biotherapeutics, Inc.

20120172410 - Short hairpin rna for gene knockdown of nr1 subunit of the n-methyl-d-aspartate receptor and its application on pharmaceutics: A short hairpin RNA (shRNA) for gene knockdown the genetic expression of NR1 subunit of N-methyl-D-aspartate (NMDA) receptor comprises a first fragment sharing homologous nucleotides among the NR1 subunit of NMDA receptor; a second fragment having complementary sequence to the first fragment; and a connecting fragment having any base in... Agent:

20120172418 - Aslv vector system: The invention provides a viral self-inactivating (SIN) vector on the basis of the avian sarcoma leukosis virus (ASLV) as well as a split-packaging system comprising in addition to the SIN vector a first helper plasmid serving for the expression of the viral fusion protein gag-pol and a second helper plasmid... Agent: Medizinische Hochscule Hannover

20120172420 - Method for modulating responsiveness to steroids: e

20120172419 - Reagents and methods for modulating cone photoreceptor activity: The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.... Agent: University Of Washington

20120172417 - System and method for identifying and applying peripheral treatment mechanisms for disease: A method and system for the identification and application of biological targets for peripheral treatment of diseases. Existing cellular mechanisms or pathways are exploited to identify novel genes or other molecule candidates that will be used to treat disease via a peripheral treatment system. Using the method, a novel Alzheimer's... Agent: Syracuse University

20120172324 - Compositions and methods for reducing the risk of agent-induced liver toxicity: The present disclosure relates generally to a co-formulation or co-administration of acetaminophen with one or more chemicals that are metabolites or their derivatives in the methionine and glutathione biosynthesis pathways, for protection against acetaminophen-induced liver toxicity. The formulation may comprise acetaminophen and diet supplements such as S-methylmethionine (SMM). The present... Agent:

20120172325 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis employing. The methods... Agent: Ironwood Pharmaceuticals, Inc.

20120172328 - Hyaluronic acid-based gels including lidocaine: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including... Agent: Allergan, Inc.

20120172326 - Moisturizing mixture, cosmetic and/or pharmaceutical compositions containing the moisturizing mixture, use of the moisturizing mixture, and cosmetic method: The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or Ichthyosis vulgaris containing a synergistic combination among its constituents, and cosmetic and/ pharmaceutical compositions containing said moisturizing mixture. The invention also refers to a moisturizing mixture comprising a synergistic combination between at least one cutaneous-barrier repairing... Agent: Natura Cosmeticos S.a.

20120172327 - Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.... Agent: Abbott Laboratories

20120172329 - Phytochemical compositions including xanthones for anti-inflammatory, anti-cytokine storm, and other uses: A composition (e.g., a phytochemical composition) including a predetermined concentration of xanthones, and in certain embodiments predetermined concentrations of both xanthones and sesamin. The composition facilitates at least one of decreasing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, enhancing a connective tissue anti- degeneration effect, and inhibiting viral neuraminidase (e.g. neuraminidase of... Agent: Thailand Excellence Center For Tissue Engineering

20120172330 - Human milk oligosaccharides for modulating inflammation: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.... Agent: Abbott Laboratories

20120172331 - Methods of using human milk oligosaccharides for improving airway respiratory health: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.... Agent: Abbott Laboratories

20120172332 - Antibacterial aminoglycoside analogs: s

20120172334 - Controlled release particles and method for producing the same: Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound in a hydrophobic polymerizable vinyl monomer without the presence of a solvent, thereby preparing a hydrophobic solution, the hydrophobic antibiotic compound having a melting point of 100° C. or less, a polar term δp,compound of 2 to 8 [(J/cm3)1/2]... Agent: Japan Envirochemicals, Ltd.

20120172333 - Pyrrolo-pyridine derivatives as activators of ampk: n

20120172335 - Substituted benzimidazolone derivatives, medicaments comprising them and their use: The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.... Agent:

20120172336 - Fosfluconazole derivatives, synthesis, and use in long acting formulations: The invention relates to a compound of formula (1) and the salts, N-oxides, quaternary amines, and stereoisomers thereof, wherein R1 to R2 are as defined in the claims. The invention further relates to intermediates and methods for the preparation of the compounds of formula (I). The invention also relates to... Agent: Seps Pharma N.v.

20120172337 - Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Esperion Therapeutics, Inc.

20120172338 - Topical gel formulation comprising organophosphate insecticide and its preparation thereof: The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a... Agent:

20120172339 - Angiogenic resorcinol derivatives: Novel resorcinol derivatives and methods of preparation and use are presented. These compounds can stimulate angiogenesis as a biological function triggered by the activation of one cannabinoid receptor distinct from CB1 and CB2. Thus, these compounds are specific ligands for one cannabinoid receptor distinct from CB1 and CB2. The invented... Agent: Northeastern University

20120172340 - Compositions and methods for selectively activating human sirtuins: Methods for identifying selective activators of SIRT5 and/or SIRT1 and methods for using these selective activators in the modulation of SIRT5 and/or SIRT1 are provided.... Agent: Biomol International L.p.

20120172341 - Compositions comprising tramadol and celecoxib in the treatment of pain: The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics, more particularly for the treatment of severe to moderate pain with an inflammation component.... Agent: Laboratorios Del Dr. Esteve, S.a.

20120172342 - Biotherapeutics for the treatment of infectious diseases: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.... Agent:

20120172343 - Pharmaceutical composition for emergency contraception: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.... Agent: Bayer Pharma Aktiengesellschaft

20120172344 - Insulin-producing cell inducer, glucose intake enhancer, and therapeutic agent for diabetes or diabetes complications: Provided is an insulin-producing cell inducer, an enhancer for glucose intake of muscles, and a therapeutic agent for diabetes or diabetes complications, wherein an active ingredient of those provided is an estrogenic compound such as estrogen and estradiol. With the present invention, functions of insulin-producing cells can be recovered since... Agent: Kyushu University, National University Corporation

20120172346 - Use of nicotinic acetylcholine receptor alpha 7 activators: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.... Agent: Novartis Ag

20120172347 - 8-oxodihydropurine derivative: The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120172345 - Heteroaryls and uses thereof: e

20120172348 - Sterol derivative: The present invention provides a sterol derivative or a pharmaceutically acceptable salt thereof having an activity to promote proliferation of neural stem cells. Namely, the present invention provides a sterol derivative represented by the general formula (I) (wherein Y represents optionally substituted lower alkyl or the like; Xa and Xb... Agent: Kyowa Hakko Kirin Co., Ltd.

20120172349 - Therapeutic compounds and compositions: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.... Agent:

20120172350 - Histamine h3 inverse agonists and antagonists and methods of use thereof: Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release... Agent: Sunovion Pharmaceuticals Inc.

20120172351 - Novel fused cyclic compound and use thereof: A compound represented by the formula (I): wherein each symbol is as defined in the specification, and a salt thereof have a GPR40 receptor activation action and is useful as an insulin secretagogue or a prophylactic or therapeutic drug for diabetes and the like.... Agent:

20120172352 - Pyrazoline dione derivatives as nadph oxidase inhibitors: The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Genkyotex Sa

20120172353 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent:

20120172354 - Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines: e

20120172355 - Aminodihydrothiazine derivatives substituted with a cyclic group:

20120172356 - Serum biomarkers for chagas disease: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.... Agent: Mcgill University

20120172357 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), dependent compounds of Formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (III), (III-A), (III-B), (III-C), (IV), (IV-A), (IV-B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the... Agent: Boehringer Ingelheim International Gmbh

20120172358 - Gpcr agonists: i

20120172359 - Oxazine derivatives and their use in the treatment of neurological disorders:

20120172360 - Novel 1h-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of akt (pkb) phosphorylation:

20120172361 - Triazine derivatives and their therapeutical applications: Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.... Agent: California Capital Equity, LLC

20120172362 - Therapeutic agent for anxiety disorders: Provided are an agent for the treatment and/or prophylaxis of an anxiety disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R1 represents aryl or the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.... Agent: Kyowa Hakko Kirin Co., Ltd.

20120172363 - Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers: The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). The present invention further relates to a method for preventing damage and death in mammalian... Agent: Ozleo Pty Ltd

20120172364 - Rate-controlled particles: e

20120172365 - Use of phosphordiesterase inhibitors in the treatment of prostatic diseases:

20120172366 - 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine derivatives as p2x7 modulators: The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain,... Agent:

20120172367 - Macrocyclic integrase inhibitors: Compound having formula (I), wherein —W is NH—, —N(CH3)— or piperazine, —X is a bond, —C(═O)— or S(═O)2—, —Y is C3-7alkylene, and —Z is NH—C(═O)— or —O—, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations and use as HIV inhibitors.... Agent: Elanco Animal Health Ireland Limited

20120172368 - Bis-benzimidazole derivatives: m

20120172369 - Inhibitors of diacylglycerol acyltransferase: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (DGAT) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired... Agent:

20120172370 - Preparation of crystalline forms of dihydropyrazolopyrimidinone: The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.... Agent:

20120172371 - Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (tdp1): A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In... Agent: The United States Of America As Represented By The Secretary, Department Of Health And Human Service

20120172372 - Ureas and their use in the treatment of heart failure: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Cytokinetics, Inc.

20120172373 - Method of treating cognitive impairments and schizophrenias: r

20120172374 - Novel tubulin inhibitors and methods of using the same:

20120172375 - Compounds and methods of promoting oligodendrocyte precursor differentiation: A method of promoting the differentiation of an oligodendrocyte precursor cell. The method includes administering to the oligodendrocyte precursor cell an effective amount of a compound capable of promoting oligodendrocyte precursor cell differentiation.... Agent:

20120172376 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors: which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3β, and methods of treatment of... Agent: Abbott Gmbh & Co. Kg

20120172377 - Pyrido[4,3-b]indoles and methods of use: New heterocyclic compounds that may be used to modulate a histamine receptor in an individual are described. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder... Agent:

20120172378 - Novel compounds: w

20120172379 - 4 substituted pyrazolopyrimidines: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120172380 - Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agent: or pharmaceutically acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted 4-(tetrazol-5-yl)-quinazoline derivatives, to pharmaceutical compositions containing the compound and to its use... Agent: Natco Pharma Limited

20120172381 - Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.... Agent: High Point Pharmaceuticals, LLC

20120172383 - Fungicidal compositions based on pyridylmethylbenzamide derivatives and at least one complex iii inhibiting compound: 1) Fungicidal compositions comprising: a) at least one pyridylmethylbenzamide derivative of Formula (I), in which the various radicals are as defined in the description; and b) at least one compound (II) capable of inhibiting the transport of electrons of the respiratory chain of mitochondrial ubiquinol:ferricytochrome-c oxidoreductase or complex III in... Agent: Bayer Sas

20120172382 - Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities:

20120172386 - Combinations comprising a vegf receptor inhibitor: A composition comprising a VEGF receptor inhibitor and a penetration enhancer and uses thereof.... Agent: Novartis Ag

20120172384 - Heterocyclylaminopyrimidines as kinase inhibitors: wherein R1 to R6 and T0 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70, Syk or JAK3 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said... Agent:

20120172385 - Ortho substituted pyrimidine compounds as jak inhibitors: wherein X1 to X3, R, R2 to R7 and AA have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including... Agent:

20120172387 - Opioids for the treatment of the restless leg syndrome: The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with restless leg syndrome (RLS).... Agent: Euro-celtique S.a.

20120172388 - Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to... Agent:

20120172389 - Treatment of fibrosing disorders: r

20120172390 - Method of treating sleep disorders using the combination of eplivanserin and zolpidem: The instant invention relates to a method of treating sleep disorders by using eplivanserin or pharmaceutically acceptable salts or esters thereof and Zolpidem by evaluating the effect of eplivanserin combined with the sleep-inducing agent Zolpidem on psychomotor/cognitive performance.... Agent: Sanofi

20120172391 - Naphthyridinone analogs as mglur5 positive allosteric modulators: In one aspect, the invention relates to naphthyridinone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with... Agent:

20120172392 - Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (ssao) enzyme activity and vap-1 mediated adhesion useful for treatment of diseases: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.... Agent:

20120172393 - (4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both... Agent: The University Of Edinburgh

20120172394 - Pharmaceutical composition for preventing or treating rheumatoid arthritis, containing rebamipide: The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be... Agent: Catholic University Industry Academic Cooperation Foundation

20120172395 - Slow-release cilostazol tablet having an improved elution rate and minimal side effects: Provided is a slow-release tablet including cilostazol as a pharmacologically active component, which is efficacious in suppressing aggregation of blood platelets and promoting vascular relaxation by inhibiting phosphodiesterase types. The slow-release cilostazol tablet has an extended elution time so that the slow-release cilostazol tablet can be taken once daily for... Agent: Korea United Pharm, Inc

20120172396 - 2-adamantylurea derivatives as selective 11b-hsd1 inhibitors: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120172397 - Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck Sharp & Dohme Corp.

20120172398 - Co-crystals of tramadol and coxibs: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses in pharmaceutical formulations for the treatment of pain.... Agent: Laboratorios Del Dr. Esteve, S.a.

20120172399 - Compounds as hypoxia mimetics, and composiitons and uses thereof: This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these... Agent:

20120172400 - Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals: The invention relates to Sulfonamides with heterocycle and oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and... Agent: Sanofi-aventis

20120172401 - Benzimidazole derivative and use as angiotensin ii antagonist: e

20120172402 - Induction of alpha helix conformations in proteins and peptides:

20120172403 - Low temperature stable solution: This invention relates to liquid concentrates of 4,5-dichloro-2-(n-octyl-4-isothiazolin-3-one) (“DCOIT”) which are stable to crystallization or freezing at sub-freezing temperatures.... Agent:

20120172404 - Antimicrobially effective use solutions comprising combinations of isothiazolones and amines: The invention relates to a microbicidal use solution which comprises a) one or more isothiazolin-3-ones and b) one or two organic amines selected from N-dodecylpropane-1,3-diamine and bis(aminopropyl)-dodecylamine and optionally c) one or more oxidizing agents. The use solution is preferably in the form of technical and domestic products.... Agent: L'air Liquide Societe Anonyme Pour L'etude Et L'explotation Des Procedes George

20120172405 - Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.... Agent: Ardea Biosciences Inc.

20120172406 - Androgen receptor antagonists and uses thereof: The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.... Agent:

20120172407 - N-alkoxycarboxamides and their use as microbiocides: Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection LLC

20120172408 - Active ingredient comprising indocyanine green and/or infracyanine green: The present invention relates to an active ingredient including indocyanine green and/or infracyanine green for use in treating dental or periodontal infectious diseases under irradiation with light, more particularly laser light, from a wavelength range between 790 nm and 830 nm.... Agent: A.r.c. Laser Gmbh

20120172421 - 2, 6 xylidine derivatives for the treatment of pain: The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of... Agent: Krisani Biosciences (p) Ltd

20120172422 - Methods of treatment using a prodrug of an excitatory amino acid: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.... Agent: Eli Lilly And Company

20120172424 - Chroman derivatives, medicaments and use in therapy: Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.... Agent: Marshall Edwards, Inc.

20120172423 - Compositions and methods for treating herpes simplex virus: Green tea polyphenol compositions and methods of their use in treating herpes simplex virus (HSV) are provided. Representative green tea polyphenols include, but are not limited to (−)-epigallocatechin-3-gallate as well as green tea polyphenols with one on more ester-linked fatty acids.... Agent: Georgia Health Sciences University Research Institute, Inc.

20120172425 - Red yeast rice extract high in monacolin k content: Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject.... Agent:

20120172426 - Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related... Agent: Reviva Pharmaceuticals, Inc.

20120172427 - (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability: The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.... Agent: Sanofi

20120172428 - Novel formulations of bifenthrin and enriched cypermethrin: The present invention is directed to novel insecticidal compositions comprising bifenthrin and enriched cypermethrin, the compositions are physically stable when diluted with water.... Agent: Fmc Corporation

20120172429 - Permanently charged sodium and calcium channel blockers as anti- inflammatory agents: The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.... Agent:

20120172430 - Compositions of dibromomalonamide and their use as biocides: A biocidal composition comprising 2,2-dibromomalonamide and 2,2-dibromo-3-nitrilopropionamide, and its use for the control of microorganisms in aqueous and water-containing systems.... Agent:

20120172431 - Omega 3 fatty acid formulations: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using... Agent: Cenestra LLC

20120172432 - Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.... Agent: Amarin Pharma, Inc.

20120172434 - Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid... Agent: Abbott Laboratories

20120172433 - Oil-in-water emulsion skin care cosmetic composition: To provide an oil-in-water emulsion skin care cosmetic composition which, without the addition of a pharmaceutical agent and a film-forming agent or the like thereto, effects an excellent elastic or resilient feeling to skin and is excellent in non-stickiness and stability. An oil-in-water emulsion skin care cosmetic composition, comprising (a)... Agent: Shiseido Company, Ltd.

20120172436 - Liver regeneration accelerator comprising betaine: The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine represented by formula 1 as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for... Agent: Snu R&db Foundation

20120172435 - Methods for treating acute acoustic trauma: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating... Agent:

20120172437 - Continuous on-line adjustable disinfectant/sanitizer/bleach generator: Methods and systems for on-site, continuous generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in... Agent: Ecolab Usa Inc.

20120172438 - Glycyrrhetinic acid ester derivative synthesis method and deoxoglycyrrhetinic acid ester compound: A compound represented by formula II, a preparation method, and uses thereof in treating liver damage and inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound represented by formula II, R1 is H, linear or branched C1-C18 alkylformyl, linear or... Agent:

20120172439 - Generation of peroxycarboxylic acids at alkaline ph, and their use as textile bleaching and antimicrobial agents: The present disclosure provides methods for generating percarboxylic acid compositions and/or peroxycarboxylic acid compositions formed external to a point of use in non-equilibrium reactions for use in certain bleaching and antimicrobial applications, in particular laundry applications. The compositions are generated external to a point of use, at alkaline pH levels,... Agent: Ecolab Usa Inc.

20120172440 - In situ generation of peroxycarboxylic acids at alkaline ph, and methods of use thereof: The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed.... Agent: Ecolab Usa Inc.

20120172441 - In situ generation of peroxycarboxylic acids at alkaline ph, and methods of use thereof: The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed.... Agent: Ecolab Usa Inc.

20120172442 - Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid... Agent: Abbott Laboratories

20120172443 - Nutritional products including a novel fat system including monoglycerides: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid... Agent: Abbott Laboratories

20120172445 - Nutritional products including a novel fat system including fatty acids: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid... Agent: Abbott Laboratories

20120172444 - Use of conjugated linoleic acid: Conjugated linoleic acid (CLA) or a derivative thereof may be used in reducing the rate of increase of fat mass in a growing child.... Agent:

20120172446 - L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin: The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.... Agent: Pierre Fabre Dermo-cosmetique

20120172447 - Composition comprising vitamin u as active ingredient for healing skin wound: Disclosed is a composition comprising vitamin U as an active ingredient, more precisely a composition for repairing the skin wound that contains vitamin U as an active ingredient. The composition demonstrates excellent wound healing and skin wound repairing effects.... Agent: Cuskin Co., Ltd.

20120172448 - Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof: The present application relates to novel substituted 1-benzylcycloalkylcarboxylic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120172449 - Polyamine transport inhibitors as novel therapeutics: Novel polyamine transport inhibitors have been synthesized and demonstrated to block the uptake of native polyamines into human cancer cells. A combination therapy of the transport inhibitor and DFMO (a drug which blocks polyamine biosynthesis) provided synergistic activity against a metastatic human colon cancer cell line. The strategy uses polyamine... Agent:

20120172450 - Use of jasmonate for improving skeletal muscle function: A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.... Agent: Broady Health Sciences, LLC

20120172451 - Cleaning liquid: The present invention relates to a cleaning fluid, in particular a cleaning fluid for cleaning surfaces.... Agent:

20120172452 - Topical nitrone spin trap compositions for psoriasis: Psoriasis is treated by application of a composition containing a nitrone spin trap such as α-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and method of treatments further comprise at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and... Agent:

20120172453 - Methods for treating neurodegenerative diseases: This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth... Agent: Coyote Pharmaceuticals, Inc.

20120172454 - Biodegradable drug delivery compositions: A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.... Agent: Medincell

20120172456 - Engineered microparticles for macromolecule delivery: b

20120172455 - Functionalized water-soluble polyphosphazenes and uses thereof as modifiers of biological agents: A polyphosphazene polymer which includes hydrophilic side groups and interacting side groups which are capable of bonding with a biological agent of interest. The bonding may be by non-covalent bonding.... Agent:

20120172457 - Novel powdered polymer, preparation method thereof and use of same as a thickener: Disclosed is a branched or crosslinked anionic polyelectrolyte of at least one monomer having a partially- or totally-salified strong acid function, with at least one neutral monomer and at least one monomer having formula (I), wherein: R represents a linear or branched alkyl radical including between 8 and twenty carbon... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seepic

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.43481 seconds

PATENT INFO